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Abstract 
Device associated urinary tract infections are a very important healthcare issue. Despite 
best efforts in preventing and treating these infections, many patients and physicians are 
still confronted with this problem. Our research group is involved in testing and 
evaluating new stent coatings for the prevention of device associated infections and 
device encrustation. In the current project, we tested two new coating copolymers, both 
based on a long chain polymer backbone and mussel adhesive protein to this purpose in a 
rabbit and porcine model. The results demonstrate efficiency of one copolymer in 
preventing infections in the rabbit model. Interestingly there is an inverse correlation 
between E. coli infections and encrustations. No significant differences were noted in the 
porcine study, the model itself however seems to have some pitfalls. Finally we identified 
that the coatings are subject to a certain shelf life. We intend to further investigate the 
coating and its potential in future research. 
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Chapter 1  
1 Background 
This chapter will provide the historical background of catheters and stents and a 
comprehensive overview of catheter associated urinary tract infection and biofilm 
formation on urinary devices. A review of previously developed devices, research 
methods and outcomes in the search for the ideal biocompatibility will demonstrate the 
extent of this field of research. The novelty of our current research will be highlighted 
and a summary of the preliminary work done by our research group will aid in the 
understanding and appreciation of this current project.  
1.1 Historic Note 
Draining the bladder in the treatment of urinary retention has been an essential part of a 
physician’s trade for millennia. Catheterisation of the bladder has been described in 
ancient Asian, Chinese, Egyptian, Roman, Byzantine and Greek civilizations (Mattelaer 
and Billiet, 1995). These descriptions report the use of straws, reeds, polished or waxed 
rolled up leaves or hollow twigs for bladder catheterisation (Mattelaer and Billiet, 1995). 
Paulus Aegineta, in the 7
th
 century AD, was the first to describe bladder drainage with a 
slender silver catheter, a technique which became very popular in medieval times 
(Mattelaer and Billiet, 1995). Even in this scientifically naïve era, silver was attributed an 
antiseptic effect. The popularity of silver catheters remained until the introduction of 
natural rubber for the manufacture of urinary catheters. Benjamin Franklin suggested the 
use of a reusable silver flexible catheter for bladder drainage to his brother who suffered 
from urinary stone disease (Gensel, 2005; Mattelaer and Billiet, 1995). The 19
th
 Century 
was pivotal in the evolution of the urinary catheter. Auguste Nelaton created a tubular 
soft bladder catheter with a solid straight tip and one side hole, made of vulcanized 
rubber in 1860, that bears his name (Mattelaer and Billiet, 1995). This design was further 
developed to hold a retaining mechanism when in the 1930’s, Frederick EB Foley 
 2 
 
constructed a catheter with an inflatable balloon attached to the catheter tip (Tatem et al., 
2013). Ever since this fundamental development, the catheter design has not changed 
much to the extent that we still use “Foley” catheters to this day.  
The use of ureteral stents in surgery has been described as early as the 19
th
 century 
(Shoemaker, 1895). The first urologist to access the ureter endoscopically was Dr. James 
Brown at Johns Hopkins Hospital in 1893 (Arcadi, 1999). Before becoming popular and 
globally used to treat obstructed kidneys, Dr. Werner Forssmann used a ureteral catheter 
to perform the first ever heart catheterization on a human, himself, in 1929. Although 
initially met with criticism, he went on to win the Nobel Prize for his pioneering 
endeavor with the ureteral catheter (Morris and Schirmer, 1990). In 1967, Zimskind was 
the first to describe the cystoscopic placement of indwelling ureteral stents for obstructed 
kidneys (Zimskind et al., 1967). As ureteral stents were straight, they were very prone to 
migration and device expulsion, which impaired widespread adoption. As with the 
urinary catheter, altered designs were suggested to include a retaining mechanism. 
Gibbons proposed and patented a barbed stent to prevent distal migration (Gibbons et al., 
1976). A few years later, Finney developed the “double J” (DJ) or double pigtail stent 
(Finney, 1978). The DJ stent was an instant success and its use was soon adopted in 
urology departments worldwide, having a tremendous positive impact on endourologic 
surgery and patient care. Today, ureteral stents are of fundamental importance to any 
urologic practice. 
 
1.2 Urinary Device Associated Urinary Tract Infection 
Bladder catheterization is an everyday practice on almost every hospital ward with 13-
25% of hospitalized patients undergoing bladder catheterisation at some point during 
their stay (Fakih et al., 2012; Glynn et al., 1997; Weinstein et al., 1999). The placement 
and presence of a urinary catheter may be associated with short and long term 
complications. Catheter associated urinary tract infection (CAUTI) is one of the most 
important complications of indwelling urinary catheters. In current guidelines, CAUTI is 
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defined as significant bacteriuria (defined by convention as >10
5
 colony forming units 
(CFU)/mL) in a patient with symptoms or signs indicating a urinary tract infection with a 
catheter in situ or within 48 hours after removal. Asymptomatic bacteriuria refers to 
significant bacteriuria in asymptomatic patients (Hooton et al., 2010). Before 2009, the 
definition of CAUTI still included asymptomatic bacteriuria. In a large prospective trial, 
Tambyah et al identified less than 10% of catheterized patients with proven bacteriuria of 
> 10³ CFU/ml to be symptomatic (Tambyah and Maki, 2000). The Infectious Diseases 
Society of America (IDSA) first recommended not screening for bacteriuria in 
catheterized patients as early as 2005 (Nicolle et al., 2005). The concept of asymptomatic 
bacteriuria being a different entity that does not need treatment was thus in place for 
about half a decade before the definition of CAUTI was nuanced in 2009 to exclude 
asymptomatic bacteriuria. Whereas symptomatic CAUTI deserves to be treated 
accordingly, bacteriuria in a catheterized patient without any symptoms does not need to 
be treated with antibiotics. The European Association of Urology (EAU) and the 
Infectious Diseases Society of America (IDSA) specifically recommend against 
screening and treatment of asymptomatic bacteriuria as there is insufficient evidence of 
its benefit (Hooton et al., 2010; Tenke et al., 2008).  
CAUTI account for approximately 35% of all hospital acquired infections (Klevens et al., 
2007). The other hospital acquired infections are categorized in surgical site infections 
(20%), pneumonias (11%), bloodstream infections (11%) and “other” hospital acquired 
infections (22%) (Klevens et al., 2007). Almost 95% of urinary tract infections in the 
intensive care unit setting are associated with bladder catheters (Richards et al., 2000). 
Several risk factors influence the incidence of CAUTI. The most important risk factor is 
prolonged catheterization greater than six days (Maki and Tambyah, 2001). Other risk 
factors include diabetes, female sex, BMI greater than 30, catheterization outside of the 
operating room, and the presence of other active sites of infection (Maki and Tambyah, 
2001; Stenzelius et al., 2011). The abundant use of urinary catheters and high incidence 
of CAUTI account for a sizeable economic impact. In the United States alone, the cost 
associated with CAUTI accumulates to about US$ 300 million annually (Zimlichman et 
al., 2013). Several quality improvement and awareness projects have been instituted and 
are adopted widely, contributing to a significant decrease in the incidence and duration of 
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catheterization, and ultimately CAUTI rates (Janzen et al., 2013; Parry et al., 2013; Saint 
et al., 2013). Some of the most important universal recommendations in guidelines for the 
prevention of CAUTI are 1) avoiding unnecessary catheter use, 2) aseptic catheter 
placement technique, 3) maintaining a closed drainage system and 4) removal of the 
catheter as soon as possible (Meddings et al., 2014; Tambyah and Oon, 2012). 
Despite best efforts, these preventive measures have not been able to completely 
eliminate urinary device associated urinary tract infections. Antibiotic prophylaxis and 
treatment of CAUTI play a definite role in eradication of CAUTI. The revised definition 
of CAUTI was instituted to prevent overtreatment of patients with antibiotics in instances 
where it is not needed. Recent research however has investigated the influence of this 
change in definition. Although it has decreased the number of CAUTIs observed, the 
clinical practice of antibiotic prescribing for asymptomatic bacteriuria has not changed 
(Cope et al., 2009; Press and Metlay, 2013). 
The antibiotic treatment and prophylaxis of CAUTI poses a challenge and has been the 
subject of debate and controversy. Multiple different regimens have been proposed and 
there is a lack of consensus. Prophylactic antibiotics upon removal of a bladder catheter, 
even after short term catheterization, have been both recommended and discouraged 
(Hooton et al., 2010; Wolf et al., 2008). The American Urological Association (AUA) 
guidelines published in 2008 recommended the use of antibiotic prophylaxis after 
catheter removal if bacteriuria was present, particularly in patients with risk factors such 
as advanced age, immunodeficiency or corticosteroid use (Wolf et al., 2008). In 2010, the 
Infectious Disease Society of America (IDSA) discouraged the use of prophylactic 
antibiotics prior to catheter removal or catheter change (Hooton et al., 2010). Lusardi et 
al performed a Cochrane meta-analysis on whether or not antibiotic prophylaxis during 
short-term catheterisation (<15 days) has any benefit (Lusardi et al., 2013). They 
compared no prophylaxis to antibiotic prophylaxis, prophylaxis with antibiotic A vs. 
antibiotic B and prophylaxis at catheter removal vs. prophylaxis throughout 
catheterisation period. Primary outcomes were asymptomatic and symptomatic 
bacteriuria. Although the meta-analysis was performed after the definition had changed, 
all the trials included in the meta-analysis were from before 2009. The authors identified 
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an overall paucity of reliable evidence supporting any conclusions. The evidence 
available indicated that antibiotic prophylaxis reduces the rate of bacteriuria compared to 
starting antibiotics when bacteriuria is identified, both in surgical and non-surgical 
catheterized patients. Taking the 2009 definition of CAUTI into account, no statements 
can be made according to this meta-analysis on whether or not antibiotic prophylaxis 
reduces the CAUTI rate in surgical or non-surgical patients. 
Marschall et al on the other hand identified in their meta-analysis that antibiotic 
prophylaxis at time of catheter removal does reduce the incidence of subsequent urinary 
tract infection (Marschall et al., 2013). They do point out however that adopting this 
practice would entail an enormous increase in antibiotics usage resulting in the potential 
for antibiotic resistance over time and a significant economic impact. Therefore, 
prophylaxis should be considered a recommendation only in patients with risk factors, as 
previously stated by the AUA guidelines panel. 
A meta-analysis comparing suprapubic to transurethral catheter drainage after 
gynecological surgery concluded that suprapubic catheterization significantly reduces the 
rate of UTI, but on the other hand was significantly associated with a higher minor 
complication rate such as hematuria, leakage, blockage or accidental catheter loss. 
Superiority of one over the other could not be determined (Healy et al., 2013, 2012). 
When long-term catheterisation is to be expected, one may consider placing a suprapubic 
catheter taking all possible advantages and disadvantages into account. 
Ureteral stents have been demonstrated to be at risk of bacterial colonization and 
therefore represent a possible source of urinary tract infection. Short-term ureteral stent 
placement (3 weeks) in a cohort of 209 children following ureteral reimplantation led to 
urinary tract infection in only 4.8% of patients (Uvin et al., 2011). Asymptomatic 
bacteriuria was reported in an additional 6.5% of patients. Despite the fact that all 
patients were receiving antibiotic prophylaxis during the indwelling period of the stent, 
almost half of the stents were colonized with bacteria. Patients with untreatable ureteral 
obstruction are often permanently managed with a ureteral stent. In these chronically 
stented patients, bacterial colonization reaches 100% (Riedl et al., 1999). Indwelling 
time, female sex, diabetes and chronic kidney disease are factors influencing colonization 
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of ureteral stents (Kehinde et al., 2002). A negative urine culture has low predictive value 
for stent bacterial colonization (Kehinde et al., 2004; Rahman et al., 2012). Similar to 
bladder catheters, routine screening for bacteriuria and treatment of asymptomatic 
bacteriuria is not recommended in patients with ureteral stents. Antibiotics are only 
recommended in instance of symptomatic urinary tract infection and appear not to have a 
role in long-term prophylaxis. A small RCT with 95 patients demonstrated that 
continuous low-dose antibiotic treatment during the indwelling time of ureteral stents 
does not influence the incidence or severity of stent-related symptoms or urinary tract 
infections (Moltzahn et al., 2013). 
1.3 Antibiotic Resistance 
The most commonly prescribed antibiotics for E. coli urinary tract infection are 
ciprofloxacin, nitrofurantoin, trimethroprim/sulfamethoxazle (TMP/SMX) and 
amoxicillin/clavulanic acid. 
Several authors have demonstrated that the resistance patterns for community-acquired 
and hospital- or catheter acquired urinary tract infections are quite different for the same 
bacterial species. Bacteria responsible for hospital acquired UTI are more frequently 
resistant to the most commonly used antibiotics (Lobel et al., 2008). In the comparison of 
85 community acquired vs 106 hospital acquired E. coli urinary tract infections, Huang et 
al demonstrated a significantly higher resistance of hospital-acquired E. coli to cefazolin, 
cefuroxim, ceftriaxone, ceftazidim, ampicillin/sulbactam, gentamicin, levofloxacin and 
trimethoprim/sulfamethoxazole (TMP/SMX) (Huang et al., 2014). Although 
susceptibility of community-acquired E. coli to these antibiotics was significantly higher, 
the actual susceptibility ranged only from 49% for cefazolin to 87 % for ceftazidim 
(Huang et al., 2014). Taking E. coli as well as other causative organism such as 
Klebsiella, Enterococcus species and Proteus into account, the overall susceptibility to 
levofloxacin, amoxicillin-clavulanate and cephalosporines was markedly higher in 
community acquired UTI compared to hospital acquired UTI (Khawcharoenporn et al., 
2012). 
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Not only is the resistance pattern of hospital-acquired urinary tract infections less 
favorable than that of community acquired UTI’s, the susceptibility to the most 
commonly used antibiotics for UTI also seems to fade with time. Sanchez et al have 
identified a significant decrease in susceptibility of E. coli to ciprofloxacin (from 97% to 
83%) and TMP/SMX (from 82% to 76%) when comparing susceptibility patterns of E. 
coli in 2000 and 2010 in the United States (Sanchez et al., 2012). Interestingly, 
susceptibility for nitrofurantoin (99.2% to 98.4%) and ceftriaxone (99.8% and 97.7%) 
were maintained throughout this period (Sanchez et al., 2012). Karlowsky and associates 
demonstrated the same trend in decreasing susceptibility in Canadian hospitals using the 
CANWARD nationwide surveillance database of the Canadian Antimicrobial Resistance 
Alliance (CARA). The authors report a significant increase of E. coli resistance to 
ciprofloxacin from 20% in 2007 to 29.2% in 2011 (P=0.0005) (Karlowsky et al., 2013). 
As Goossens et al pointed out, increased antimicrobial resistance is probably due to a 
higher use of antibiotics (Goossens et al., 2005). This increase in antibiotic resistance 
may in part be attributed to inappropriate antibiotics use such as antibiotic treatment of 
asymptomatic bacteriuria, long-term low-dose prophylaxis in catheterized patients and a 
short-term antibiotics course where a long-term may be more appropriate. 
If this trend continues, bacterial strains responsible for community or hospital acquired 
urinary tract infections will become so resistant that our current empirical antibiotic 
therapy will be insufficient and we will have to resort to broad-spectrum IV antibiotics 
for the treatment of simple, uncomplicated UTI’s. 
The insufficient effectiveness of preventive measures for CAUTI such as reduced 
catheterization and continuous monitoring and re-evaluation of catheter need and the 
increasing antimicrobial resistance of bacterial strains responsible for device associated 
urinary tract infections has encouraged the search for increasing biocompatibility of 
urinary devices. To improve biocompatibility of urinary devices, new biomaterials for 
device manufacturing as well as several coatings have been developed to prevent biofilm 
formation and urinary tract infection. 
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1.4 Biofilm 
The most commonly used definition of the term biofilm is attributed to Costerton who 
defined it as “a structured community of bacterial cells enclosed in a self-produced 
polymeric matrix and adherent to an inert or living surface” (Costerton et al., 1999). 
Essential elements of biofilm are bacteria, exopolysaccharides and an attachable surface. 
A biofilm is conceptually a survival mechanism for bacteria to remain in a favorable 
environment. Bacteria within a biofilm have limited exposure to harmful factors (the 
host’s immune response, antimicrobial agents and waste products) while enhancing the 
exposure to trophic factors and promoting reproduction. 
As previously indicated, foreign bodies implanted in the urinary tract become colonized 
over time with 90-100% of ureteral stents reaching colonization in chronically stented 
patients (Reid et al., 1992; Riedl et al., 1999). Trautner and Darouiche indicated that 
biofilm on the urinary device is the most important factor in inducing catheter associated 
urinary tract infections (Trautner and Darouiche, 2004). Presence of a biofilm or attached 
bacteria on the urinary device however does not necessarily translate into a positive urine 
culture or clinical infection (Reid et al., 1992; Uvin et al., 2011). 
A mature biofilm consists of three distinct layers: (1) the innermost layer or conditioning 
film is deposited onto the surface of the biomaterial and functions as a linking film for 
bacterial cells and subsequent layers, (2) adhesions of micro-organisms to the linking 
film form the base film and (3) once matured, the outer layer or surface film of the 
biofilm can release micro-organisms (Tenke et al., 2012). Ganderton et al measured the 
thickness of biofilm on urinary catheters and noted a range from 3 to 490 µm composed 
of multiple cell layers ranging from just a few to up to 400 cells deep (Ganderton et al., 
1992). 
The innermost layer of the biofilm, the conditioning film, is deposited onto the 
biomaterial surface as an initial step in biofilm formation. This initial deposition can take 
place within minutes of insertion (Reid et al., 1995). This conditioning film is composed 
 9 
 
of urinary components such as albumin, immunoglobulins, Tamm-Horsfall protein, 
cytokeratins, polysaccharides, electrolytes and glycoproteins that adhere to the 
biomaterial surface (Canales et al., 2009; Elwood et al., 2013; Santin et al., 1999). The 
surface characteristics of the biomaterial are altered due to these depositions, facilitating 
bacterial adhesions (Reid and Busscher, 1992). The initial bacterial adhesion which is 
still reversible, is influenced by hydrophobic and electrostatic interactions, ionic forces, 
osmolality and urinary pH and is still reversible (Gristina, 1987). After attaching to the 
conditioning film, bacteria produce a matrix of exopolysaccharides and glycocalix, 
enveloping the micro-colonies and rendering their adhesion irreversible (An and 
Friedman, 1998). Eradication of the biofilm with antibiotics at this point is extremely 
difficult and almost impossible due to several defense mechanisms of the biofilm as will 
become clear in the following paragraphs. Approximately 5-35% of the biofilm consists 
of bacterial micro-colonies. The remainder of the biofilm consists of matrix and 
interstitial spaces. These interstitial spaces contain water channels which are filled with 
fluid, allowing transportation of nutrients and oxygen to the colonies (Tenke et al., 2012). 
Micro-organisms present or embedded in biofilm react differently to antibiotic substances 
compared to planktonic micro-organisms. Ceri et al demonstrated that the concentrations 
of antibiotics (ampicillin, ciprofloxacin, cefazolin, cefotaxime, TMP/SMX) needed to 
eradicate E. coli embedded in biofilm are 1000-fold higher or more than the 
concentration needed for eradication of cultured planktonic E. coli (Ceri et al., 1999). 
Similar concentrations were needed to eradicate Pseudomonas aeruginosa or 
Staphylococcus aureus from biofilm compared to planktonic Pseudomonas or S. aureus 
(Ceri et al., 1999). This relative resistance to antimicrobial treatment of bacteria 
embedded in biofilm is multifactorial: 
(1) Bacteria in micro-colonies and biofilm have a means of communicating with each 
other so that they can respond to the environment in unison, as a multicellular organism. 
This communication, termed Quorum Sensing, occurs through the bacterial production of 
signaling molecules called auto-inducers and is population density-dependent (McLean et 
al., 1997; Salmond et al., 1995; D. J. Stickler et al., 1998). Once a population of bacteria 
reaches a certain threshold density or ‘quorum’, the cumulative level of signaling 
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molecules reaches a threshold concentration at which quorum sensing is allowed to 
regulate the biofilm’s response and subsequently induces a population-wide gene 
expression, thus responding as one behavioral unit or multicellular organism (Fuqua et 
al., 1994). Quorum sensing is reported to play a role in biofilm formation, swarming, 
biofilm virulence, biofilm dispersion and antibiotic resistance (Bhardwaj et al., 2013; 
González Barrios et al., 2006; Li and Nair, 2012; Solano et al., 2014). 
(2) The polymicrobial nature of biofilm with the potentially variable susceptibility 
patterns for each organism may account for the difficulty in treating biofilm induced 
infection. Frank and associates analysed micro-organisms present in biofilm from urinary 
catheters in a culture-independent manner (Frank et al., 2009). Using 16S rDNA 
sequencing and PCR amplification to identify the bacteria embedded in the biofilm, the 
authors identified Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus 
epidermidis, Streptococcus pneumoniae, Escherichia coli, Enterococcus faecalis, and 
Propionibacterium acnes in the specimens and concluded that biofilm is usually 
polymicrobial (Frank et al., 2009). Hola et al reported that most of urinary catheters 
collected from in-hospital patients have three to six different micro-organism present on 
the catheter surface (Holá et al., 2010). Only 12% had a monomicrobial infection. 
Escherichia coli, Enterococcus faecalis, Pseudomonas aeruginosa and Candida albicans 
were isolated most frequently (Holá et al., 2010). As the shared gene-pool of a 
polymicrobial biofilm is advantageous or even necessary for its survival, bacteria seem to 
actively recruit other bacterial strains and species to their mutual synergistic benefit 
(Wolcott et al., 2013). 
(3) A third factor contributing to antibiotic resistance is the presence of “persister cells” 
in biofilm. Persister cells contribute up to 1% to a biofilm and appear to be a dormant 
variant of a regular bacterial cell (Keren et al., 2004). They neither grow nor die and are 
thus not antibiotic resistant but rather antibiotic tolerant (Lewis, 2010; Wood et al., 
2013). When the concentration of the antibiotic decreases, the persister cells can 
reproduce and repopulate the biofilm (Lewis, 2010). Dormancy is believed to be induced 
by a variety of toxin/antitoxin systems where the toxin stops the metabolic activity of the 
cell and the antitoxin can reverse this process (Keren et al., 2004; Lewis, 2012). Recent 
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research indicates that persister cells can be induced by subinhibitory dosage of antibiotic 
therapy, suggesting that long-term low-dose antibiotic prophylaxis can actually play a 
role in multi-drug resistant recurring urinary tract infections (Goneau et al., 2014).  
(4) Although antibiotic agents may be able to penetrate the biofilm to reach the embedded 
bacteria, their antibacterial mechanism of action may be compromised or inactivated due 
to the micro-environment created within the biofilm. The metabolic activity of the high 
density of micro-organisms in the biofilm produces a large amount of waste products, 
altering among others the pH and pO2 level as well as the pyrimidine concentration 
within biofilm (del Pozo and Patel, 2007; Stewart and William Costerton, 2001). 
The fast deposition of conditioning film and the complex architecture and multiple 
survival mechanisms of the biofilm entity render biofilm and biofilm associated 
infections extremely difficult to prevent or treat. 
 
1.5 Encrustation 
Minor encrustations on a stent or catheter surface are encountered frequently and usually 
do not cause stent or catheter blockage. With increasing amount of encrustation on the 
surface or in the lumen of the stent or catheter, this problem becomes more clinically 
relevant as it can result in stent or catheter blockage or resistance at attempt of removal of 
the urinary device. 
1.5.1 Dependent on Urinary Composition 
The deposition of encrustations on urinary devices is pH dependent. Hedelin et al 
demonstrated that a urinary pH of approximately 6.8 is critical to the composition of 
encrustations (Hedelin et al., 1991). Below this pH, the precipitations mainly consisted of 
calcium phosphate (~ HydroxyApatite), whereas above this threshold pH, they are 
composed of magnesium ammonium phosphate (~Struvite) (Hedelin et al., 1991). 
Choong et al corroborated these results identifying a urinary pH of approximately 7 as a 
threshold pH above which precipitation occurs. The authors termed this the nucleation 
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pH (pHn) (Choong et al., 1999). In a subsequent paper, Choong demonstrated that 
patients that have encrusted urinary catheters have a pH in the voided urine that is higher 
than the pHn, thus explaining why they form encrustations more easily (Choong et al., 
2001). This nucleation pH is subject to change by modulating urinary constituent 
concentrations. An increase of [Ca²
+
], [Mg²
+
] and [phosphate] decreases the nucleation 
pH at which these constituents precipitate, whereas the addition of citrate increases the 
pHn
Ca
 (Suller et al., 2005). 
The presence of urease-producing bacteria may be a prerequisite to the formation of 
encrustations. The urea-splitting enzyme catalyzes the hydrolysis of urea into carbonic 
acid which deprotonates and ammonia, which becomes protonated at physiological pH, 
thus increasing urinary pH (Mobley and Hausinger, 1989). 
(NH2)2CO + 2 H2O  H2CO3 + 2 NH3 
H2CO3  H
+
 + HCO3
- 
2NH3 + 2H20  2NH4
+
 + 2OH
-
 
Stickler et al identified Proteus mirabilis, Proteus vulgaris and Providencia rettgerii to 
be the most potent urease-producing bacteria, able to increase urinary pH well above 8.0 
(D. Stickler et al., 1998). Broomfield et al equally identified these bacteria to have higher 
encrustation rates due to more potent urease activity when compared to for example E. 
coli, Klebsiella pneumonia and Pseudomonas aeruginosa (Broomfield et al., 2009). Once 
precipitations are formed, they can deposit onto the catheter surface and will get 
embedded in the polysaccharide matrix (Morris et al., 1999). 
In contrast to encrustations formed in biofilm containing urease-producing bacteria, the 
encrustations that form on stents inserted in stone formers are usually composed of 
calcium oxalate, reflecting the most common stone composition in urolithiasis patients 
(Bithelis et al., 2004). Calcium oxalate as the major component of stent encrustation was 
previously reported to occur in the absence of UTI, at pH values <5.5 and in presence of 
hyperuricosuria, (Grases et al., 2001; Robert et al., 1997).  
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Canales et al identified components of the conditioning film, alpa-1-anti-trypsin, Ig 
Kappa, IgH G1 and histone H2B and H3A, to be highly associated with stent encrustation 
(Canales et al., 2009). Tamm-Horsfall protein and α1-microglobulin may have an 
encrustation protective effect by stabilizing the organic conditioning film and by 
inhibiting calcium oxalate aggregation (Santin et al., 1999). Santin et al demonstrated that 
these proteins where only present in the conditioning film of non-encrusted stents and not 
on encrusted stents (Santin et al., 1999). 
Additional risk factors for stent encrustation that depend on the urinary composition 
include urinary tract infection, history of stone disease, urinary diversions, pregnancy, 
metabolic or congenital abnormalities and chronic renal failure (Ahallal et al., 2010; 
Robert et al., 1997; Vanderbrink et al., 2008). Figure 1 A and B demonstrate grossly 
visible encrustations on stents retrieved from stone formers. Biochemical analysis 
revealed the same composition as the stones the patients formed. 
 
Figure 1: A: Stent retrieved from cystine stone former; B: Stent retrieved from uric 
acid stone former. 
 
1.5.2 Dependent on Indwelling Time 
Next to the previously mentioned influencing factors, indwelling time of the urinary 
device is the most important influence on the development of encrustation. Encrustation 
has been reported to occur in 9.2-26.8% of stents indwelling <6 weeks, in 47.5-56.9% of 
stents indwelling 6 to 12 weeks and in approximately 75% of stents indwelling longer 
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than 12 weeks (el-Faqih et al., 1991; Kawahara et al., 2012). Kawahara additionally 
reported complete stent obstruction in 8.6% of stents after >12 weeks and 1 % of stents 
requiring additional treatments to facilitate stent removal (Kawahara et al., 2012). The 
authors observed stents smaller than 6F to be significantly more prone to encrustations 
than stents of 7Fr or larger (Kawahara et al., 2012). To prevent severe encrustations, 
timely stent removal or exchange is an important preventive measure. Most stent 
manufacturers recommend stent removal or exchange within 4 months of placement. In 
patients with additional risk factors for encrustation a 6-8 week interval is recommended 
(Aravantinos et al., 2006). Stent exchange is suggested every 4-6 weeks for pregnant 
patients as this population is particularly prone to stent encrustation (Denstedt and Razvi, 
1992). 
All the previously reported influencing factors however cannot always explain or predict 
the extent of encrustations found on ureteral stents or urinary catheters. Whereas some 
stents will be encrusted after only a few weeks of indwelling time, in some cases a 
forgotten stent can show virtually no encrustations even after very long periods of time, 
which is demonstrated in Figure 2. 
 
Figure 2: Forgotten stent retrieved from a patient with urinary tract stones after 
two years of indwelling time, showing no appreciable encrustations. 
 
 15 
 
1.6 Urinary Catheter Biomaterials and Coatings 
The ideal biomaterial to use for urinary devices should be chemically stable in urine, 
prevent infection and encrustation, cause no significant discomfort to the patient, be 
biocompatible, have excellent long-term urinary flow and be affordable (Beiko et al., 
2004). The most commonly used catheters are manufactured from latex, rubber, silicone 
or polyvinylchloride (PVC). Due to widespread availability and lower cost, latex or 
rubber catheters are preferred for short-term use. Silicone is relatively inert and 
randomized controlled trials (RCT’s) have demonstrated silicone to induce significantly 
less tissue inflammation and encrustation than latex catheters (Bruce et al., 1974; Nacey 
et al., 1985; Schumm and Lam, 2008; Talja et al., 1990). Silicone is therefore preferred 
over latex catheters for long term catheterization.  
Several coatings have been studied in an attempt to reduce trauma, urethritis and CAUTI. 
Coatings of interest to our research are coatings preventing encrustation and device 
associated urinary tract infection. Coatings with the goal of reducing trauma or catheter 
associated discomfort other than infection and encrustation will therefore not be 
discussed here. An important issue in interpreting the results of research on catheter 
coatings preventing CAUTI, is that many of the papers report on bacteriuria as a primary 
outcome and not on symptomatic CAUTI. As it is now appreciated that bacteriuria is of 
low significance in these patients and should not even be screened for in catheterized 
patients, it may be difficult to compare different approaches in the prevention of CAUTI. 
It is therefore also not always possible to make statements as to whether or not a certain 
coating has the ability or the potential to decrease CAUTI. 
Antibiotic-impregnated silicone catheters have been evaluated in randomized trials in 
the past. Darouiche et al evaluated the use of Minocyclin and Rifampin impregnated 
catheters in radical prostatectomy patients. In their cohort of 124 patients, they 
demonstrated a statistically significant benefit of antimicrobial catheters in preventing 
bacteriuria, both at day 7 (15.2% versus 39.7%) and at day 14 (58.5% versus 83.5%) 
(Darouiche et al., 1999). It was however later demonstrated that Minocyclin/Rifampicin 
impregnated catheters have only a low activity against Gram negative bacteria and no 
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significant effect on enterococci, yeasts, or enterobacteriaceae (Schierholz et al., 2002). 
These catheters have therefore not been widely adopted and are no longer available. Both 
norfloxacin and gentamicin impregnated catheters have been investigated in vitro. 
Where Gentamicin-coated catheters had demonstrated efficacy against Proteus vulgaris, 
Staphylococcus aureus and Staphylococcus epidermidis over a short time period (Cho et 
al., 2003), the Norfloxacin catheters conveyed considerable inhibitory effects against 
Escherichia coli, Klebsiella pneumoniae and Proteus vulgaris over a 30 day period (Park 
et al., 2003). In vivo trials however have not been pursued. Nitrofurazone catheters have 
been studied more extensively, have been marketed and are more widely accepted. In 
vitro studies have demonstrated the efficacy of nitrofurazone impregnated catheters 
against common as well as multi-resistant uropathogens (Johnson et al., 1999, 1993). 
Nitrofurazone-coated catheters have been extensively studied in comparison to uncoated 
or silver-alloy-coated catheters and have almost unanimously been demonstrated to have 
a significant influence on reducing catheter associated bacteriuria (Desai et al., 2010; 
Pickard et al., 2012; Regev-Shoshani et al., 2011; Stensballe et al., 2007). Hachem et al 
recently researched the activity of an antiseptic coating based on chlorhexidine and 
gentian violet: Gendine (Hachem et al., 2009). The gendine-coated catheters appeared to 
prevent both biofilm formation and CAUTI. No human trials have been conducted to 
date. 
The first large randomized controlled trial comparing silver-oxide coated silicone- 
catheters to a silicone-coated latex catheter was published in 1995 and demonstrated that 
the silver-coated catheters had no benefit with regards to bacteriuria (Riley et al., 1995). 
Karchmer et al conducted a single-center, hospital-wide crossover study comparing 
silver-alloy coated latex catheters to silicone-coated latex catheters, including 27,878 
patients in the trial and using 11032 study catheters (Karchmer et al., 2000). The authors 
reported a reduced rate of bacteriuria per 1000 patient days, per 100 patients and per 100 
catheters placed in the silver-coated catheter cohort. They additionally estimated that the 
systematic use of silver-coated catheters would be cost-effective. Another large-scale, 
prospective, crossover study comparing silver-alloy coated silicon-based urinary 
catheters to non-coated silicon urinary catheters including 3036 patients, could not 
identify a significant benefit of the silver coated catheter over a non-coated silicone 
 17 
 
catheter for the prevention of bacteriuria (Srinivasan et al., 2006). In a more recent 
multicenter RCT including over 6000 patients, nitrofural-impregnated silicone catheters 
demonstrated a statistically significant benefit in reducing CAUTI compared to PTFE-
coated latex catheters (control), whereas silver-alloy coated latex catheters demonstrated 
no benefit in reducing CAUTI (Pickard et al., 2012). Although a statistical difference was 
noted for the nitrofural-impregnated catheters, this difference was too small to be 
regarded as clinically significant. As no clinically significant benefit was noted for short 
term catheterization by either catheter, Pickard et al conclude that the routine use of these 
catheters cannot be recommended (Pickard et al., 2012). 
In a systematic review of antimicrobial urinary catheters in the prevention of CAUTI, 
Johnson et al indicate that both the use of nitrofural- as silver-alloy coated catheters 
reduces catheter associated bacteriuria in short-term use (Johnson et al., 2006). A 2008 
Cochrane meta-analysis of types of catheters used in short-term (≤ 14 days) 
catheterisation in adults, demonstrated that the use of nitrofurazone- and silver-alloy 
coated catheters but not silver-oxide coated catheters significantly reduced the incidence 
of asymptomatic bacteriuria in short-term (>1week) use of such catheters (Schumm and 
Lam, 2008). Silver-alloy catheters demonstrated a benefit for longer than one week, 
whereas nitrofurazone catheters could not (Schumm and Lam, 2008). Silver-oxide 
catheters are no longer available. A 2012 Cochrane meta-analysis showed no difference 
in urinary infection rates in long-term (> 30 days) catheterized patients when comparing 
different catheter types (Jahn et al., 2012). Although these meta-analyses may indicate 
that silver-alloy coated and nitrofurazone-impregnated catheters may reduce bacteriuria 
rates in short-term catheterized patients, no statements can be made regarding the 
influence on catheter associated urinary tract infections (Hooton et al., 2010). Taking the 
more recent large multicenter RCT’s into account, there is currently insufficient evidence 
to reliably recommend the systematic use of one catheter type over another for short-term 
catheterization. 
The discrepancy in reported effectiveness of silver-coated urinary catheters may rely on 
the base compound on which the silver is coated or the compound of the catheter to 
which the silver-coated catheter is compared to. Crnich et al interestingly reanalyzed the 
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data from a systematic review on antimicrobial coated catheters (Johnson et al., 2006) 
and identified a difference in UTI-preventing efficacy of silver-coated catheters when 
compared to latex- or silicone catheters (Crnich and Drinka, 2007). The benefit of silver-
coated catheters over silicone catheters is much smaller than over latex catheters. As 
previously indicated, an additional factor influencing the differences in effectiveness of 
silver-coated catheters is the type and manner of silver-coating onto the device. 
As the spinal cord injured (SCI) population have a higher need for chronic catheterization 
and are at higher risk of urinary tract infections due to neurogenic bladder disorders, the 
results from previously performed RCT’s in non-spinal cord populations may not be 
suited for extrapolation to the SCI population. Bonfill et al published a methodology 
paper announcing an ongoing RCT in which they intend to compare the effectiveness of 
silver-alloy-coated, nitrofural-impregnated and PTFE-coated catheters on the reduction of 
UTI in SCI patients (ESCALE: Efficacy Study of Antimicrobial Catheters to Avoid 
Urinary Infections in Spinal Cord Injured Patients) (Bonfill et al., 2013). The trial is 
registered on clinicaltrials.gov and is reported as currently recruiting participants 
(NCT01803919). 
Studies on the feasibility and efficacy of clinical use of bacterial coated catheters are 
ongoing (Darouiche and Hull, 2012; Prasad et al., 2009; Trautner et al., 2007). They have 
the theoretical benefit of colonizing the urine with a non-virulent strain of E. coli and 
have shown promising results in small pilot trials. 
Hydrogel coatings have been applied on catheters to render the surface more hydrophilic. 
The absorption of water by the coating increases the surface lubricity, facilitating catheter 
insertion and reducing possible trauma (Lawrence and Turner, 2005). Hydrogel-coatings 
on indwelling urinary catheter do not unanimously decrease bacteriuria. Kumon et al 
demonstrated that hydrogel-coated catheters had a lower bacterial attachment rate than 
uncoated latex catheters in an in vitro study (Kumon et al., 2001). Erickson et al could 
not identify a significant difference in UTI rate or stricture rate between hydrogel-coated 
latex catheters versus silicone catheters in a urethroplasty cohort (Erickson et al., 2008). 
In an in vitro study comparing uncoated silicone and latex catheters to hydrogel-coated 
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and hydrogel/silver coated catheters, the authors demonstrated that uropathogens 
migrated most easily over hydrogel-coated catheters, insinuating that they may even 
facilitate catheter associated urinary tract infections (Sabbuba et al., 2002). Additionally, 
Morris demonstrated that hydrogel-coated latex catheters were blocked with 
encrustations more rapidly than silicone-coated latex catheters or uncoated silicone 
catheters (Morris and Stickler, 1998). Yang et al developed a Chitosan/poly(vinyl 
alcohol) hydrogel coating on polyurethane catheters that demonstrated high lubricity and 
antiseptic effects on E. coli in an in vitro setting, identifying its potential for future 
developments (Yang et al., 2007). 
The use of hydrophilic coated catheters is of interest in patients performing clean 
intermittent catheterization (CIC). Such catheters have been associated with less 
discomfort, fewer traumatic catheterizations and a decreased incidence of symptomatic 
UTI and urethral strictures in this population (Cardenas et al., 2011; De Ridder et al., 
2005; Wyndaele, 2002). A recent meta-analysis by Bermingham was unable to identify a 
significant difference in the incidence of symptomatic UTI’s when comparing different 
catheter types used for CIC. Li et al on the other hand, in a meta-analysis focusing on the 
spinal cord injury population, demonstrated that the use of hydrophilic coated catheters 
for use in CIC significantly reduced UTI and hematuria rates (Bermingham et al., 2013; 
Li et al., 2013). As the use of clean non-coated catheters for CIC is most cost-effective, 
and the use of gel-reservoir second most cost-effective in the Bermingham analysis 
(Bermingham et al., 2013), the routine use of hydrophilic catheters for CIC in non-spinal 
cord injury patients was not recommended.  
New coatings to enhance biocompatibility are still being developed and investigated with 
the desired outcome of preventing encrustation and urinary tract infections (Siddiq and 
Darouiche, 2012). 
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1.7 Indications for Stent or Catheter Placement 
The indications for inserting an indwelling bladder catheter are numerous and can 
conveniently be divided into two categories: therapeutic or diagnostic catheterization. 
This includes catheterization for drainage of urinary retention, drainage after 
reconstructive surgery, monitoring of urinary output, bladder irrigation of gross 
hematuria and urethral dilation with urethral catheters. The wide indication for urinary 
catheterisation accounts for its widespread adoption and abundant use to the extent that 
the urinary catheter is one of the most commonly placed foreign bodies in humans. 
Ureteral stents are most commonly placed to relieve ureteral obstruction. Intrinsic 
obstruction is typically caused by stones, tumors or strictures, whereas extrinsic 
obstruction is often due to compression by tumor, overlying vessels, retroperitoneal 
fibrosis or lymphadenopathy. The need for obstruction relief can be temporary or 
permanent. Ureteral stents are also frequently placed prior to shockwave lithotripsy 
treatment or after ureteroscopic treatment of urinary lithiasis after which one may expect 
some edema or residual fragments of the stone to obstruct the ureter. The most recent 
guidelines and literature dictate narrower indications for stent placement in these 
instances (Al-Awadi et al., 1999; Ather et al., 2009; Shen et al., 2011a, 2011b; Song et 
al., 2012; Tang et al., 2011; Türk et al., 2013). Stents have proven utility in ureteral 
trauma treatment and reconstructive urological procedures. A particularly important and 
well-studied post-operative use of ureteral stents is after renal transplantation. A recent 
meta-analysis in the renal transplant population demonstrated that routine prophylactic 
stenting significantly reduces the incidence of major urological complications (Wilson et 
al., 2013). 
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1.8 Stent Technology 
The ideal stent is easy to insert, is chemically stable after implantation in a urinary 
environment, has the ability to relieve intraluminal and extraluminal obstruction, has 
excellent flow characteristics, does not induce patient symptoms and is resistant to 
encrustation and infection. The biocompatibility of the biomaterial or coating at the stent 
surface is of the utmost importance for the prevention of UTI and encrustation. The 
prevalence of stent related symptoms, encrustation and infection are the main drive for 
the research and development of new stent biomaterials and coatings. As the worldwide 
business of DJ stents covers several billion dollars in revenue, industry driven research 
for new compounds and coatings is very prevalent. The number of new patents filed 
annually related to ureteral stents is shown in Figure 3 and demonstrates that 
development of new designs, biomaterials and coatings for ureteral stents has increased 
dramatically over the past decade. This once more reflects the vast amount of research 
dedicated to improving biocompatibility of ureteral stents with the ultimate goal of 
reducing stent-related symptoms and infections. 
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Figure 3: Graph showing number of patents filed annually related to ureteral stents. 
Courtesy of Dolcera Patent and Market Research Services. 
 
1.8.1 Biomaterials 
Initially ureteral stents were manufactured from silicone (Zimskind et al., 1967), which is 
still the most biocompatible material tested to date (Cormio et al., 1995; Pariente et al., 
1998). However, due to the high friction coefficient, flexibility and low tensile strength 
that are characteristics of silicone, silicone stents are more difficult to insert and may be 
especially challenging to navigate through a tortuous or obstructed ureter (Mardis et al., 
1993). Polyethylene was introduced as the first plastic polymer used in the commonly 
utilized DJ stents (Mardis et al., 1979). Polyethylene stents however, have a tendency to 
become brittle after prolonged exposure to the urinary environment and are prone to 
encrustation, blockage and fragmentation. This led to its discontinuation in stent 
manufacture and the development of newer polymers. Currently utilized stents are 
commonly composed of polyurethane, silicone or proprietary copolymers such as 
Silitek®, C-flex®, Percuflex® or Tecoflex®. The large choice of different stents 
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available allows the urologist to tailor the choice of stent to the needs and characteristics 
of the patient in need of a stent. Multiple authors have compared different stent 
biomaterials and copolymers with the goal of identifying the ideal stent biomaterial. 
Mitty et al were the first to publish preliminary results on the Percuflex® stent (Mitty et 
al., 1988). Marx et al observed that C-Flex® and silicone stents induced less 
inflammation than Silitek® or polyurethane stents in a canine model (Marx et al., 1988). 
Mardis et al identified C-Flex® and Percuflex® to be the most suitable copolymers for 
stent manufacturing as they have the best combination of biocompatibility, biodurability, 
surface friction coefficient, tensile strength, flow capacity and coil retention strength 
(Mardis et al., 1993). Tunney et al identified Silitek® to be the copolymer most resistant 
to hydroxyapatite encrustations (Tunney et al., 1996).  
Metallic mesh or coil stents such as the Resonance® stent, the Memokath 051® stent, 
the Allium® stent or the Uventa® stent, have been utilized in the treatment of 
obstructed ureters in which a conventional ureteral stent is unable to relieve the 
obstruction. This is most commonly due to external compression of the ureteral lumen, 
often by a malignant process, causing high radial forces that conventional stents are 
unable to withstand. Conversely, the most important trait of these metal mesh or coil 
stents is that they can withstand these high radial compressive forces (Blaschko et al., 
2007; Pedro et al., 2007).  
A common problem among metal mesh stents is reduced patency in long-term follow-up 
and late complications such as migration, encrustation, erosion and tissue hyperplasia 
growing into the stent (Agrawal et al., 2009; Chung et al., 2013; Goldsmith et al., 2012; 
Kadlec et al., 2013; Liatsikos et al., 2010; Moskovitz et al., 2012; Papatsoris and 
Buchholz, 2010). Coatings to prevent or limit hyperplasia and stent ingrowth in metal 
mesh stents have been adopted from the endovascular stent realm. Liatsikos et al 
demonstrated a paclitaxel drug-eluting metal mesh stent to reduce inflammation and 
hyperplasia of the surrounding tissue compared to a bare metal stent (BMS) in a porcine 
model (Liatsikos et al., 2007). The use of a zotarolimus-eluting metal stent compared to a 
BMS has been shown to induce a significantly lower hyperplastic reaction without 
influencing inflammation rates in a porcine and rabbit model (Kallidonis et al., 2011). 
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These cytostatic drug coatings have the potential to improve patency and reduce 
complication rates of metal mesh ureteral stents. 
Since the late 1990’s, experimental biodegradable ureteral stents have been evaluated 
with the goal to eliminate the necessity of cystoscopic stent removal and the possibility of 
forgotten stents (Lumiaho et al., 1999; Schlick and Planz, 1997; Talja et al., 1997). The 
biodegradable materials assessed to date are composed of high molecular weight 
polymers such as polylactide (polylactic acid: PLA), polyglycolide (polyglycolic acid: 
PGA) or variants to these (Lumiaho et al., 1999; Talja et al., 1997). The surface of 
bioresorbable stents can be chemically modified with for instance 
hydroxyethylmethacrylate (HEMA), oligo(ethyleneoxide)-monomethacrylate (OEOMA), 
or acrylic acid (AAC) and has been demonstrated to improve biocompatibility in vitro 
without increasing toxicity of these polymers (Brauers et al., 1998, 1997). The main 
challenge of biodegradable materials is controlling the rate of degradation. This can be 
influenced by environmental (urinary pH) and stent-related factors such as basic 
molecular structure, the degree of the polymerization and the internal arrangement of the 
material components (Lumiaho et al., 1999). In vivo tests with a poly-L,D-lactide 
polymer in a canine model demonstrated promising results with complete degradation of 
all stents within 24 weeks without inducing ureteral histologic changes (Lumiaho et al., 
2000, 1999). Schlick and Planz demonstrated a pH-dependent controlled degradation of 
biodegradable copolymers that were stable at a pH of 5.2 and completely dissolved 
within 20 hours at a pH of 7.9 (Schlick and Planz, 1998). Olweny et al evaluated the use 
of poly-L-lactide-co-glycolic (PLGA) as a degradable stent in a porcine ureter after 
endopyelotomy (Olweny et al., 2002). Although the stents degraded, they induced more 
tissue inflammation than a conventional stent (Olweny et al., 2002). 
Uriprene
TM
 is a biodegradable copolymer composed of L-glycolic acid, polyethylene 
glycol and barium sulfate showing promising preliminary results in a porcine in vivo 
model. In its current chemical formulation, Uriprene™ stents reliably achieve 
degradation after four weeks (Chew et al., 2013). When compared to conventional DJ 
stents, The Uriprene
TM
 stents induced a lower degree of ureteral inflammation in a 
porcine model (Chew et al., 2013, 2010b; Hadaschik et al., 2008).  
 25 
 
Most recently MagnesiumYttrium alloy has been investigated in vitro for potential 
bacterial growth inhibition and biodegradability (Lock et al., 2012). The mode and rate of 
degradation can be influenced through surface modification and alloy design (Lock et al., 
2014, 2012).  
The only in vivo human trial published to date studying the use of biodegradable stents 
demonstrated adequate drainage while maintaining a high patient tolerance (Lingeman et 
al., 2003). After 90 days, 96.6% of patients were stent-free. Three patients however 
required SWL and one patient subsequently required ureteroscopy to clear retained stent 
fragments. Currently, Uriprene
TM
 is being evaluated for feasibility after uncomplicated 
ureteroscopy in an ongoing trial (NCT02032316). 
 
1.8.2 Coatings 
Coatings on stent biomaterial are often employed to improve biocompatibility of the 
device. They may be anti-fouling (preventing deposition of conditioning film 
constituents), anti-microbial, lubricating or drug-eluting. 
Hydrogel coatings have been applied to urinary catheters as well as ureteral stents. They 
are composed of hydrophilic polymers that absorb water, thus reducing friction and 
rendering the stent easier to insert and theoretically more biocompatible. In vitro tests 
however have not consistently shown a decrease in encrustation rate on hydrogel coated 
stents. Similar to urethral catheters, hydrogel coated stents have been demonstrated to 
both reduce and increase encrustation and biofilm formation (Desgrandchamps et al., 
1997; Gorman et al., 1998; Tunney et al., 1996). Choong et al even demonstrated in an in 
vitro setting that hydrogel-coated stents (Microvasive Percuflex with Hydroplus) are 
significantly more prone to encrustation than uncoated silicone stents (Choong et al., 
2000). 
Urinary device surfaces coated with Phosphorylchlorine (PC) were hypothesized to be 
more biocompatible because PC resembles the major polar head group on the outer 
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surface of erythrocytes. After performing in vitro and in vivo preliminary clinical human 
tests, Stickler et al concluded that PC-coated stents did not stop biofilm formation and 
encrustation on these devices (Stickler et al., 2002). 
Polyvinylpyrrolidone-iodine (PVP-I) complex modified polyurethane Tecoflex® stents 
appear to be highly hydrophilic and reduce encrustation deposits and adherence of 
Pseudomonas aeruginosa and Staphylococcus aureus by 80-86% in in vitro tests 
(Khandwekar and Doble, 2011). Tunney and Gorman had previously tested PVP-coated 
catheters, which have been marketed and are available as the Bard Inlay® stent, in vitro, 
comparing the stent to uncoated polyurethane and uncoated silicone stents (Tunney and 
Gorman, 2002). The authors demonstrated the PVP-coated stent to be more lubricious 
than the other two stents in addition to improved resistance to bacterial attachment and 
encrustation (Tunney and Gorman, 2002). 
Diamond-like carbon coatings have shown great benefit in improving biocompatibility of 
vascular, orthopaedic and other medical implants (Roy and Lee, 2007). Applying a 
diamond-like carbon (DLC) coating onto a polyurethane surface appears to decrease 
surface friction dramatically, thus improving biocompatibility (Jones et al., 2006). In the 
only trial published to date, Laube et al demonstrated that DLC-coated polyurethane 
significantly reduced biofilm formation and microbial adherence in 10 patients, compared 
to previously used stents in the same patient population. (Laube et al., 2007). 
The observation of the absence of Oxalobacter formigenes and a lack of calcium oxalate 
(CaOx) stone formation induced the development and research of silicone stents coated 
with Oxalobacter formigenes derived oxalate degrading enzymes (Watterson et al., 
2003a). The authors demonstrated a lesser degree of encrustation as compared to non-
coated controls in a rabbit model, however the findings were not statistically significant 
(Watterson et al., 2003a). 
Triclosan is an antibacterial and antifungal agent commonly used in deodorants, soap, 
detergent and many consumer products. In vitro evaluation of the efficacy of 
Triclosan®-eluting stents (Triumph®) in artificial urine compared to non-coated 
Percuflex® stents demonstrated reduced bacterial attachment to the stent and growth 
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inhibition of Enterococcus faecalis, Klebsiella pneumoniae, Staphylococcus aureus, and 
Proteus mirabilis (Chew et al., 2006). A subsequent in vivo rabbit study showed the 
Triumph® stent to significantly reduce growth and survival of Proteus mirabilis 
(Cadieux et al., 2006). A preliminary human study in 8 patients with long-term stents 
demonstrated the Triclosan-eluting stents to reduce but not eliminate device associated 
urinary tract infection (Cadieux et al., 2009). The stent was further evaluated in a small 
randomized trial comparing it to the Percuflex® stent for short indwelling periods. 
Although the Triumph® stent did not significantly reduce infection, biofilm or 
encrustation, it did reduce other stent-related symptoms such as flank pain and urethral 
pain during urination (Cadieux et al., 2009; Mendez-Probst et al., 2012). 
Glycosaminoglycans (GAGs) have been shown to inhibit calcium oxalate crystal growth 
in vitro. Heparin appears to be the strongest inhibitor among the GAGs available 
(Senthil et al., 1996; Yoshimura et al., 1997). Hildebrandt et al performed in vitro and in 
vivo (rat model) tests with heparin coated tantalum and stainless steel stents and 
demonstrated substantially fewer encrustations on the coated devices (Hildebrandt et al., 
2001). The first in-human randomized trial with heparin coated stents demonstrated the 
coated stents to be free from encrustations after 6 weeks of indwelling time, in contrast to 
uncoated stents that had biofilm and encrustations present on all of the stents (Riedl et al., 
2002). Although these numbers are based on a small series, Tenke and Cauda noted that 
heparin-coated stents may remain indwelling for longer than 6 months and potentially up 
to 12 months without being affected by encrustations, translating into a possible 
economic benefit (Cauda et al., 2008; Tenke et al., 2004). In contrast to these positive in 
vivo results, Lange et al demonstrated no significant difference in biofilm formation on 
commercially available heparin-coated stents compared to a Triumph® stent and 
uncoated stents when tested in vitro in artificial urine incubated with 5 different species 
of uropathogens (Lange et al., 2009).  
Pentosan polysulphate (PPS) is a semi-synthetic GAG related to heparin. It has been 
shown to inhibit CaOx crystallization in vitro (Martin et al., 1984). Zupkas et al identified 
uncoated silicone disks to have significantly more encrustations than PPS coated silicone 
disks after remaining in a rabbit bladder for 50 days (Zupkas et al., 2000). Although 
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Jones and Monga appreciated the potential of PPS in a review on the use of the substance 
in prevention of CaOx stone disease and identified the need for a randomized, double-
blind, placebo-controlled trial, the use of PPS in the prevention of CaOx stones has not 
been revisited since (Jones and Monga, 2003). 
Inspired by the antifouling characteristics of placoids in shark skin, Carman et al turned 
to biomimicry to develop micropatterned surfaces. The most efficient studied thus far 
which is called Sharklet AF
TM
, has demonstrated antifouling characteristics by 
inhibiting settlement of spores of marine algae (Carman et al., 2006; Schumacher et al., 
2007). Reddy et al have applied this technology to surfaces used in urinary environment 
and demonstrated that micropatterned surfaces inhibit colonization and migration of E. 
coli on silicone in artificial urine (Reddy et al., 2011). This very promising novel 
technology will undoubtedly be further investigated in the prevention of device 
associated urinary tract infections. 
Sustained release chlorhexidine varnish is an antimicrobial method first described and 
frequently used in the world of dentistry and orthodontics (Balanyk and Sandham, 1985; 
Beyth et al., 2003). Applying a 1% chlorhexidine sustained release varnish on stent 
surfaces appeared to significantly reduce bacterial growth and biofilm formation in vitro 
(Shapur et al., 2012). Increasing the dose to a 2% concentration prolonged the inhibitory 
effect on bacterial growth from 1 to 2 weeks (Segev et al., 2013; Shapur et al., 2012; 
Zelichenko et al., 2013). A preliminary in vivo trial on dogs with the 1% formulation 
demonstrated less bacterial attachment and reduced biofilm formation when compared to 
uncoated catheters. 
The development of antibiotic stent coatings is still in a preliminary phase. In vivo 
experiments on rat models have shown promising results for Rifampin coated stents in 
combination with systemically administered Tigecycline and for Clarithromycin coated 
stents in combination with systemic Amikacin (Cirioni et al., 2011; Minardi et al., 2012). 
No human trials have been performed yet. 
In contrast to urethral catheters, silver as an antimicrobial agent has not been as widely 
evaluated on ureteral stent surfaces. Multanen et al have coated biodegradable stents with 
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silver nitrate to improve biocompatibility (Multanen et al., 2002). They demonstrated that 
coating a poly-L-lactic acid biodegradable stent with silver nitrate and ofloxacin 
accelerated stent degradation and decreased encrustation on the surface. There are no 
other publications mentioning stent surfaces coated with silver. 
Our research group has developed a novel copolymer coating for urinary biomaterials 
based on a long chain polymer backbone conjugated with DOPA, (Surphys-095). 
Preceding copolymer compound coatings leading to the current coating have previously 
demonstrated in vitro resistance to bacterial attachment and biofilm formation (Ko et al., 
2008). A cross-linked DOPA-anchored antifouling polymer was identified as the most 
resistant to E. coli adherence (Pechey et al., 2009). 
 
1.9 mPEG-DOPA 
The strategy of almost all of the ureteral stent coatings mentioned above is binding an 
anti-fouling polymer onto the device surface to prevent deposition of fouling constituents 
and bacterial cells on the surface. The efficacy of coated polymers relies on the 
mechanism of immobilization of the polymer to the surface. Where this can be obtained 
by a physisorptive mechanism, which relies on physical bonds between molecules and 
surfaces, such as Van der Waals’ forces, a chemisorptive mechanism, which relies on a 
chemical bond between surface and polymer, may procure more stability. 
1.9.1 Polyethylene Glycol (PEG) 
Polyethylene glycol (PEG) which is often referred to as polyethylene oxide (PEO) has 
been extensively studied for its anti-adhesive characteristics, preventing protein 
deposition and bacterial adhesion on surfaces (Jeon and Andrade, 1991; Jeon et al., 1991; 
Kingshott et al., 2003; Kjellander and Florin, 1981; Lu et al., 2000). The anti-fouling 
capability of PEG is thought to rely on multiple factors including PEG density, PEG 
chain length, molecular weight and immobilization technique. Jeon et al established that 
high polymer surface density and longer PEO chain length theoretically influence 
attractive Van der Waals and hydrophobic forces and steric repulsive energy, inducing 
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optimal coating characteristics for protein resistance (Jeon and Andrade, 1991; Jeon et 
al., 1991). Creating a copolymer surface coating that has a high density of PEG, 
conferring these theoretical characteristics to a surface has been shown to be quite a 
challenge (Kingshott et al., 2003; Lu et al., 2000). PEG, PEG derivates or PEG 
copolymers can be attached on surfaces (PEGylation) by a range of methods including 
adsorption and covalent attachment to a surface anchoring molecule (Holmberg et al., 
1997). Holmberg et al compared different PEGylation methods of PEG on solid 
polyethylene for both PEG density and antifouling properties using a PEG molecule of 
3000-4000 Dalton (Da) (Holmberg et al., 1997). They demonstrated that covalent 
bonding or adsorption of copolymers can procure the same density of PEG onto a 
surface. However, as the anti-fouling characteristics were different for each of the 
methods, they concluded that the immobilization method was more important than the 
PEG density. In subsequent research using PEG of 5 kDa on silica surfaces on the other 
hand, the same research group conversely showed that both PEG adsorption onto a 
surface and chemically grafting onto a surface have similar results provided that PEG is 
grafted in high density indicating that PEG density and PEG molecular weight (chain 
length) are more important than the grafting method (Malmsten et al., 1998). Kingshott et 
al then again concluded from their research evaluating different PEGylation strategies 
(with 5kDa PEG) on bacterial adhesions that the coating’s effectiveness is strongly 
dependent on the PEG immobilization strategy (Kingshott et al., 2003). Not only is it of 
importance to coat PEG onto a surface in high density, a robust grafting mechanism of 
the coating onto the surface is preferable so that the surface can retain its anti-fouling 
characteristics. Park et al grafted polyurethane surfaces with PEG polymers of different 
chain length and with different end-groups and evaluated their resistance to E. coli and S. 
epidermidis attachment in different media (Park et al., 1998). The authors identified all 
coatings to significantly resist E. coli infection in both broth and plasma with results 
varying between 80% and >90% reduction. It should be mentioned however that a 90 % 
reduction of 10E7 CFU is still 10E6 CFU and that the efficacy of the coating from a 
clinical point of view is relative. After reviewing the available literature on PEGylation of 
surfaces, Dalsin et al pointed out that most PEG coating strategies lack the versatility to 
allow for wide application of the coating onto different surfaces under different 
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circumstances (Dalsin et al., 2005). Dalsin and his colleagues were inspired by 
biomimicry and turned their efforts to developing alternative PEG grafting methods 
based on mussel adhesive protein (Lee et al., 2002). 
 
1.9.2 Mussel Adhesive Protein (MAP) 
The Blue Marine Mussel, Mytilus edulis, has the unique ability to attach to any wet 
surface through filamental threads (byssus) attaching to an adhesive pad on the object’s 
surface, both produced by the mussel (Waite and Tanzer, 1981). While the threads consist 
mainly of collagenous and silk-like protein (Benedict and Waite, 1986; Qin and Waite, 
1995), the adhesive pad is composed of polyphenolic mussel adhesive protein (MAP) 
(Waite and Tanzer, 1981). Waite et al identified that 3,4-dihydroxyphenylalanine 
(DOPA) containing decapeptides are the main component of these MAP (Waite, 1983). 
He subsequently postulated that it is this DOPA functional group that is largely 
responsible for the chemisorption of these polymers to surfaces underwater and for the 
adhesive covalent cross-linking (Waite, 1990), a statement later corroborated by Yu et al 
(Yu et al., 1999). The adhesive properties where further emphasized by the work of Yu 
and Deming, who synthetically formed aqueous solutions of L-Lysine/DOPA copolymers 
(Yu and Deming, 1998). The authors demonstrated that these copolymers could form 
moisture-resistant adhesive bonds on surfaces and that with increasing proportion of 
DOPA in the copolymer, the adhesive potential increased 10-fold (Yu and Deming, 
1998). Optimal adhesive bond strength on surfaces such as steel, glass or aluminum, is 
strongly influenced by the method of oxidization, pH and temperature at which this 
chemical process is performed (Yu and Deming, 1998). From a biomimetic point of view, 
the strong adhesive characteristics of 3,4-DOPA and the possibility of synthetically 
altering DOPA-containing copolymers tailored to the adhesive needs, were soon seen as 
an asset for industrial applications.  
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1.9.3 mPEG-DOPA 
Envisioning the mussel adhesive protein as an anchoring protein to attach molecules to a 
surface, Dalsin et al realized the anti-fouling potential of 3,4-DOPA (Dalsin et al., 2003; 
Lee et al., 2002). Through chemical and enzymatical processes, they were able to 
produce DOPA-modified PEG copolymers capable of forming hydrogels (Lee et al., 
2002). The anti-fouling characteristics of PEG and its ability to resist protein adsorption 
rely mainly but not solely on repulsive steric forces of PEG, hydration or water 
structuring of the coating, the surface polymer density as grafted on the surface and PEG 
chain length (Chen et al., 2008; Vermette and Meagher, 2003). By altering the chemical 
process and PEG structure, hydrogel properties can be tailored to the physical needs (Lee 
et al., 2002). In subsequent work, they compared hydroxyl-terminated methoxy-PEG 
(mPEG-OH) surface coatings to DOPA-conjugated mPEG surface coatings on gold (Au) 
and titanium (Ti) surfaces and identified an mPEG-DOPA 5K coating (single DOPA 
molecule conjugated to methoxylated PEG of 5kDa molecular weight) to confer strong 
anti-fouling properties to the coated Au and Ti surfaces whereas the mPEG-OH coating 
had no anti-fouling effects on the tested surfaces (Dalsin et al., 2003). Where DOPA 
supplies the strong adhesive to anchor mPEG to the surface, PEG supplies the antifouling 
properties in this copolymer. By analyzing the differently treated surfaces with X-ray 
photo-electron spectroscopy (XPS) and time-of-flight secondary ion mass spectrometry 
(TOF-SIMS), they demonstrated that PEG was densely attached to the surface of mPEG-
DOPA coated surfaces, whereas the mPEG-OH treated surfaces demonstrated only a 
modest presence of PEG molecules on the surface. This indicates the difficulty of 
efficiently coating PEG onto a surface and explains why the mPEG-OH coated surfaces 
had no anti-fouling effects. Continuing their work with mPEG-DOPA, they demonstrated 
that an mPEG-DOPA coating is rapidly and irreversibly adsorbed onto a surface, 
providing it with strong anti-fouling abilities (Dalsin et al., 2005). Furthermore, Lee et al 
demonstrated that DOPA can bind both on organic and inorganic surfaces even in the 
presence of water and that the interaction between DOPA and a Ti surface is the strongest 
single molecule binding interaction reported to date (Lee et al., 2006). 
 
 33 
 
1.10 mPEG-DOPA Coating For Urinary Devices. 
Previous research has demonstrated the mPEG-DOPA copolymer coating to prevent 
adhesion from fibroblasts (Dalsin et al., 2003; Statz et al., 2005), algae and zoospores 
(Statz et al., 2006), protein (Dalsin et al., 2005) and bacterial cells (Statz et al., 2008) 
onto a coated surface. These promising anti-fouling results of coated metal surfaces 
induced the concept of coating mPEG-DOPA onto urinary devices with the purpose of 
preventing or reducing biofilm formation, encrustation and device associated urinary tract 
infection. 
Ko et al aimed to ascertain the anti-fouling/anti-bacterial qualities of the coating under 
urinary circumstances in vitro (Ko et al., 2008). The authors submersed TiO2-coated 
silicone disks, half of which were coated with mPEG-DOPA3, in sterile pooled human 
urine and exposed the surfaces to an inoculum of any of 6 different uropathogens: 
Pseudomonas aeruginosa PAO1, Escherichia coli GR-12, Klebsiella pneumoniae 3α, 
Enterococcus faecalis 23241, Proteus mirabilis 296, and Staphylococcus epidermidis 
26585. After 24h of exposure, they could identify a uniform film on the surface of the 
non-coated devices which was not present on the mPEG-DOPA3-coated ones. They 
subsequently compared bacterial attachment data of coated vs. uncoated devices and 
demonstrated an almost 20-fold reduction of Pseudomonas attachment and a more than 
200-fold reduction for E. coli, Enterococcus and Proteus on the mPEG-DOPA3-coated 
surfaces. Scanning electron microscopy and Energy Dispersive X-ray Spectroscopy 
identified a conditioning film on the non-coated devices and the presence of crystalline 
depositions mainly consisting of Calcium, Phosphate and Magnesium, which were 
largely absent on the coated devices. With their research, they had demonstrated that the 
surface of mPEG-DOPA3-coated devices, when exposed to a simulated urinary 
environment, can resist deposition of urinary constituents and adherence of bacterial cells 
(Ko et al., 2008). 
Founded on these results, Pechey et al used an in vivo rabbit cystitis/CAUTI model to 
determine the anti-fouling and anti-bacterial properties of mPEG-DOPA3 coated devices 
(Pechey et al., 2009). They aimed to compare the robustness and durability of a linear 
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(Surphys(S)-002) vs. a cross-linked mPEG-DOPA3 coating (S-008 and S-009). Rabbits 
were randomized to have one of 5 possible stent curls placed into the bladder 
transurethrally: uncoated Sof-Flex
®
, uncoated Percuflex Plus
®
(a hydrogel coated stent), 
or Sof-Flex
®
 coated with S-002, S-008 or S-009, and were all inoculated with 10
7
 of E. 
coli. The stent curls were left in place for 7 days and urine samples were taken on Day 1, 
3 and 7 via suprapubic aspiration. They identified the group of rabbits with an S-009-
coated stent curl in situ to be more efficient in clearing an induced urinary tract infection 
compared to any of the other groups (P<0.05). Virtually all stent curls had bacterial 
attachments present on the surface, with S-009-coated devices showing the lowest 
amount of CFU/cm². This was however not statistically significant. All stent curls 
without exceptions had encrustations on the surface. The hydrogel coated stent curls had 
significantly more encrustations than the uncoated stent curls but no significant 
differences could be demonstrated between the coated and uncoated stent curls. They did 
however find that stents retrieved from sterile urine had more encrustations than stents 
from heavily infected (>10
8
) bladders (P= 0.028). Additionally, the SEM pictures 
depicted that encrustations from infected bladders, arranged more as microspheres, were 
differently structured than from non-infected bladders which appeared more as large 
crystalline structures. In vitro testing of the coated devices equally identified S-009 as the 
most efficient coating in resisting bacterial attachment. They thus demonstrated that a 
cross-linked mPEG-DOPA3 coating has a more efficient anti-fouling effect than a linear 
mPEG-DOPA3 coating (Pechey et al., 2009). 
1.10.1 S-095 and the Use of Additional Bactericidal Agents 
The preliminary work of Pechey and co-workers has helped in the continuous search for 
and development of newer and more efficient mPEG-DOPA3 inspired coatings. To 
increase the efficiency and anti-microbial activity of the coating, a new copolymer was 
developed (S-095) and silver nitrate particles (AgNO3) and quaternary amines were 
added to increase bactericidal effect of the coating. PEG was replaced with a newly 
developed proprietary long chain polymer backbone. The dual antibacterial effect with 
use of silver particles (active anti-microbial effect) in the combination with a PEGylated 
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surface (passive anti-fouling) has been reported by Ho et al (Ho et al., 2004). When the 
bactericidal effect of silver particles dependent on release from the coating and contact 
with the bacteria subsides due to depletion of the Ag, the PEGylated surface retains its 
bacteria-repelling properties and thus the antimicrobial effect of the coating. Li et al had 
previously demonstrated the dual bactericidal properties of a coating containing both Ag 
particles and immobilized quaternary amines (Li et al., 2006). The use of the 
PEG/Quaternary amine combination has been proven to be biocompatible on one hand 
and have a high bactericidal effect on the other hand (King et al., 2014).  
Silver dissociates from the coating and is able to interact with and cross the bacterial cell 
membrane of both Gram+ and Gram- bacteria. Once inside the cell, silver can interfere 
with the DNA and enzymatic function of the cell, mediating cell death (Eckhardt et al., 
2013). The bactericidal effect of quaternary amines is a kill-by-contact principle, where 
the quaternary amines disrupt the bacterial outer cell membrane and the cytoplasmic 
membrane of both Gram+ and Gram- bacteria (Gottenbos et al., 2002; Tiller et al., 2001) 
We hypothesize that the triple symbiotic effect of S-095, silver and immobilized 
quaternary amines will confer a superior anti-bacterial effect to the coating and the coated 
surface. 
Ammonia treated polyurethane surfaces were coated by chemisorption with S-095 
through a dipping method. Quaternary amines were immobilized on the surface and silver 
nitrate was added to the coating through a subsequent dipping method. The exact details 
regarding the development and composition of this coating cannot be disclosed due to 
proprietary restrictions by DSM (DSM Biomedical, Exton, PA, USA). 
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Figure 4: Schematic presentation of coating: Loops and lines are S-095. Grey orbs 
are AgNO3 particles. Red arrows point at quaternary amines immobilized on S-095. 
 
The two coatings that were eventually constructed for in vivo experiments were 
developed with two different densities of S-095. For coating A, the dipping solutions had 
an S-095 concentration of 2mg/ml whereas the dipping solution for the application of 
coating B had an S-095 concentration of 10 mg/ml. Initially several other dipping 
solutions at concentrations of 1mg/ml and 5mg/ml were also tested. The devices coated 
with different densities of S-095 were subsequently air dried and afterwards all dipped in 
the same dipping solution to add silver with a concentration of 0.25mg/ml AgNO3 by 
crosslinking it to the coating. 
Post-coating testing for the presence of silver particles demonstrated that the amount of 
particles present was directly correlated with the surface density of S-095 and that a 
second dip in the silver solution confers even more silver particles onto the coating 
(Figure 5A and B). 
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Figure 5: A: plot diagram demonstrating the correlation between S-095 density and 
silver load on the coating. B: Bar chart demonstrating that double dipping results in 
higher AgNO3 concentrations on the coating. 
When implanting a device into a human body, it is of the utmost importance that that 
device has been thoroughly and efficiently sterilized, which for polyurethane commonly 
is established with ethylene oxide (EO) gas. Although this is the safest method of 
sterilizing polyurethane catheters (Shintani, 1995), the effect of EO on experimentally 
coated polyurethane is unknown. As EO and its metabolites may accumulate on the 
surface (Lucas et al., 2003), cytotoxicity tests were in order both before and after EO 
sterilization and to determine residual levels of EO. The coatings were tested before and 
after sterilization with EO in order to verify that the coated devices retain their anti-
microbial properties. Coated devices passed both 10993-5 and 10993-7 tests for allowed 
cytotoxicity levels for implantable devices and allowed levels of residual EO on the 
device after sterilization respectively. 
In vitro analysis demonstrated excellent efficiency of both the 2mg/ml and 10mg/ml S-
095 coatings against both Gram-positive and Gram-negative uropathogens. Both coatings 
significantly decreased the number of both planktonic bacteria and of bacteria attached to 
the surface. These in vitro experiments were repeated after EO sterilization, 
demonstrating that the coatings retained their activity after the sterilization. 
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1.10.2 Pilot Study 
In the core project of this research, the goal is to identify the antimicrobial ability of a 
coated device to clear or prevent a urinary tract infection from an inoculated individual in 
an in vivo animal model. The control group to which we will be comparing our results 
should therefore ideally have a urinary tract infection during the experiment, which will 
be induced at time of device placement. The pilot study was performed to identify the 
ideal E. coli load inoculum that would induce an infection in the control group without 
inducing urosepsis. If an animal with an uncoated device in situ can clear the infection, 
we hypothesized that it should be able to clear that infection at least equally as easy or 
easier with our experimentally coated stent in situ. We used Escherichia coli GR12, a 
bacterial strain initially isolated from a patient with pyelonephritis (Hagberg et al., 1983; 
Svanborg Edén et al., 1983). This human isolate has been used previously by our group in 
numerous in vitro experiments and a rabbit study involving ureteral stents and has shown 
to persist and induce an inflammatory response similar to a human urinary tract infection 
(Pechey et al., 2009). 
 
1.10.2.1 Identifying The Ideal Inoculum To Use In The Rabbit Study 
To identify the ideal inoculum to use to induce a urinary tract infection in the animals of 
the rabbit study, we performed a pilot study on 6 rabbits. All of the rabbits were 
catheterized with an uncoated polyurethane catheter as described in (3.1.1). Half of the 
rabbits were inoculated with 10E7 of E. coli GR 12 and the other half was inoculated 
with 10E8 of E. coli GR12. Urine samples were collected at day zero, one, three, five and 
seven under anesthesia as described in (3.1.2). On day 7, the animals were sacrificed after 
anesthesia and the urinary catheters were collected. Data on urinary bacterial counts and 
bacterial attachment were quantified as described in 3.3.1 and 3.3.2. The results of this 
pilot study indicated a bacterial inoculum with 10E8 of E. coli to be more successful and 
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consistent at inducing a urinary tract infection and bacterial attachment on the catheters 
than using a 10E7 inoculum of E. coli. 
 
1.10.2.2 Identifying The Ideal Inoculum To Use In The Porcine 
Study 
To identify the ideal inoculum to use to induce a urinary tract infection in the animals of 
the porcine study, we performed a pilot study on 8 pigs. Four of these pigs were stented 
bilaterally with an uncoated polyurethane stent whereas the other four pigs were not 
stented. The procedure was performed as described in (3.2.1). Half of the pigs of each 
group were inoculated with 10E6 of Escherichia coli GR 12 and the other half was 
inoculated with 10E7 of E. coli GR12. Urine samples were collected at day zero, one, 
three and seven under anesthesia as described in (3.2.2). On day 7, the animals were 
sacrificed after anesthesia. All animals in the 10E7 group had a positive urine culture on 
day 7 whereas only 2 animals had a positive urine culture at endpoint in the 10E6 group. 
It should be mentioned that the two animals having a positive urine sample at day 7 in the 
10E6 group were stented. The amount of bacterial attachment on the stents was similar in 
both groups. Bacterial attachment was quantified as described in (3.2.3). The results of 
this pilot study demonstrated a bacterial inoculum with 10E7 of E. coli to be more 
successful at inducing a urinary tract infection than using a 10E6 of E. coli. 
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Chapter 2  
2 Materials and Methods 
The study was approved by the University of Western Ontario animal use subcommittee 
(Appendix 1). As mentioned previously, the novel coatings evaluated in this project were 
developed based on the results of prior research and noted to contain a new DOPA-
anchored long chain polymer backbone with the addition of silver nitrate and quaternary 
amines. Two different coatings (henceforth referred to as coatings A and B) were tested 
in this experiment, both containing a different amount of S-095. The test devices were 
coated with the two experimental coatings by DSM (DSM Biomedical, Exton, PA, USA), 
sterilized and packaged separately. 
Our objective was to evaluate whether or not these new coatings containing silver and 
quaternary amines would be as effective in an in vivo model. As the rabbit model had 
previously been shown to be suitable for preliminary testing of urinary devices (Cadieux 
et al., 2006; Morck et al., 1994, 1993; Multanen et al., 2002; Olson et al., 1989), it was 
selected for our initial in vivo work . To test ureteral stents coated with our experimental 
coating compound, we chose a porcine model for our in vivo experiments. The porcine 
model provides a urinary tract that resembles the macroscopic human urinary tract fairly 
well and is a very accessible animal for laboratory testing. 
All animals were allowed an acclimatization period of at least three days in the animal 
testing facility after arrival, prior to experimentation. Laboratory feed and drinking water 
were provided ad libitum during their entire stay, including before and during 
experimentation.  
The animal subjects were provided with environmental enrichment in accordance to 
species-specific standard operating protocol (SOP). The temperature and humidity of the 
housing space was monitored daily, and animals were provided with a cycle of 12 hours 
of light followed by 12 hours of darkness. 
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2.1 Rabbit Study 
A total of 36 New Zealand White (NZW) male rabbits were randomized 1:1:1 to one of 
three transurethral catheter groups. The number of animals per group was determined by 
a power analysis based on the number of recovered bacteria from urine samples in 
previously performed studies (Chew et al., 2006; Pechey et al., 2009). Given a desired 
power level of 0.8 and a p-value of 0.05, a sample size of 12 animals in each of the 3 
groups will allow detection of a 30% to 40% difference between treatment means. 
The study consisted of 3 experimental runs of 12 rabbits per run. Each set of 12 rabbits 
were randomly assigned to the 3 experimental groups in the following manner: 4 rabbits 
assigned to the uncoated catheter group, 4 to the coating A group and 4 to the coating B 
group. This breakdown allowed for uniform representation of each device type on a given 
test day. The veterinary surgical team was blinded to treatment groups by assigning each 
rabbit with a generic clinical number. The laboratory technician was then blinded to these 
labels during post-experimental sample analysis. 
 
2.1.1 Transurethral Catheter and E. coli Bacterial Challenge 
The rabbits in the control group were catheterized with a 5 French (Fr), 15 cm length of 
uncoated polyurethane catheter. The rabbits in the intervention groups were catheterized 
with a 5Fr 15 cm long polyurethane catheter coated with coating A or coating B. On day 
0, all rabbits were anaesthetized for catheter placement and bacterial challenge. Rabbits 
were anaesthetized intramuscularly (IM) using ketamine (5 mg/kg body weight) in 
combination with medetomidine (0.15 mg/kg body weight). Rabbits were intubated 
during anesthesia and maintained during the procedures via inhalation isoflurane (1.5-
5.0%). During anesthesia, the anticholinergic glycopyrrolate (0.01 mg/kg SQ) was given. 
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During anaesthesia, rabbits were placed in a supine position and the penis was cleaned 
using two consecutive alcohol preps. A 5Fr catheter from one of the study groups was 
inserted into the bladder (Figure 6).  
 
Figure 6: 5Fr transurethral catheter used for insertion in rabbit. 
The external section was initially attached to the skin with a stitch to prevent it from 
migrating further into or out of the bladder. After encountering issues with catheter 
migration despite this precaution in the first twelve animals, the catheters placed in the 
subsequent animals were attached to the skin with the aid of a wingtip (catheter 
attachment aid device resembling butterfly wings that can be placed on the catheter and 
has small holes in to thread a suture through for more secure skin attachment) that was 
attached to the catheter. No migrations were noted after this adjustment to the procedure. 
The bladder was then instilled with 10E8 colony forming units (CFU) of the uropathogen 
Escherichia coli GR12 in a 1.5 ml saline solution, followed by 0.5 ml of saline to flush 
any remaining bacteria from the inside of the catheter into the bladder. The catheter was 
clamped for 30 minutes to prevent bacterial washout and to facilitate the establishment of 
infection in the bladder. Before reversing anesthesia, the animal was given the anti-
inflammatory meloxicam (0.3 mg/kg subcutaneous (SC)) and analgesic buprenorphine 
(0.05 mg/kg SC or IM). After the procedure, atipamezole (stock at 5 mg/mL - volumetric 
equivalent of medetomidine is given) was given to reverse the anaesthetic effects and 
speed up animal recovery. This anesthesia regimen was suggested and performed by the 
veterinarian of the animal care facility. 
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2.1.2 Sample Collection 
Urine and blood samples for culture analysis were collected at day 0, prior to the 
procedure during the same anesthesia and at day 1, 3, 5 and 7 under a short anesthesia. 
The same anesthesia regimen as previously described was used for sample collection.  
Blood samples were taken by venipuncture in an ear vein after skin disinfection using an 
alcohol swab. Venipuncture was performed using a 22 gauge needle, collecting 
approximately up to 1 ml of venous blood according to SOP. Urine sample was taken 
aseptically by suprapubic, transcutaneous aspiration with a 20 gauge needle after 
prepping the skin at puncture site with an alcohol swab. This procedure was performed 
after clamping the catheter for approximately 30 minutes so that the bladder would 
contain urine for collection. A suprapubic sample was preferred versus collecting the 
sample through the catheter so as to prevent contamination from skin bacteria or from 
attached bacteria in the catheter lumen. 
Anesthesia was reversed after sample collection except on Day 7. All rabbits were 
euthanized on Day 7 following anaesthesia using 110 mg/kg intravenous sodium 
pentobarbital. Following euthanasia, autopsy was performed to collect the implanted 
device and to collect bladder, ureter and kidney tissue for histopathology analysis. A 
representative segment of kidney, ureter and bladder were dissected separately for tissue 
bacterial count analysis. Histopathology samples were submersed in formalin and stored 
until analysis. All other collected samples and tissue were stored at -80°C following 
sample collection until time of analysis. 
 
2.2 Pig Study 
In the porcine study of this project, we used 48 pigs of approximately 3 months old, 
weighing approximately between 30 and 35 kilograms. For the porcine part of our animal 
study, we applied a somewhat different approach. Whereas in the rabbit study, we had 3 
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groups comparing outcomes of control catheters to catheters coated with A or B after an 
E. coli challenge, we had an additional group of pigs stented with uncoated stents and 
with a saline challenge. This group was added to identify the influence of the devices on 
tissue inflammation and infection. A total of 48 pigs were randomized to one of four 
groups in a 1:1:1:1 ratio of uncoated control stent with saline challenge, uncoated control 
stent with E. coli challenge and coating A or coating B with E. coli challenge. The 
control stent was a 7Fr uncoated polyurethane stent (Cook Urological, Bloomington, IN, 
USA). The coated stents were also 7Fr polyurethane stents treated with either coating A 
or coating B respectively. Pigs were randomly assigned to treatment groups through an 
Excel column random order generator. 
Of the 24 pigs in the control group, half (N=12) was inoculated with a bacterial challenge 
of 10E7 of E. coli GR 12 in a 5 ml saline solution (the uncoated catheter E. coli challenge 
group, henceforth UnEC) whereas the other half was inoculated with normal saline 
containing no bacterial load (the uncoated catheter saline challenge group, henceforth 
UnS). The surgeon was blinded to the contents of the 5ml syringe containing bacteria or 
saline solution. All animals in both groups stented with coated stents were inoculated 
with a bacterial challenge of 10E7 of E. coli GR 12 in a 5 ml saline solution. These four 
groups of 12 pigs per group were divided into two different time schedules. Half of the 
animals in each group were randomized into being stented for a period of 6 days: the 
short-term stented group. The other half in each group was randomized into being stented 
for 13 days, thus allowing a longer period of exposure of the stents and tissues to the 
bacterial or saline challenge: the long-term stented group. At the allocated endpoint of 
indwelling time of the stents, pigs were euthanized and tissue and urinary devices were 
collected. A flowchart of the timeline is demonstrated in Figure 7. 
We based our calculation on the number of pigs to be allocated in each group on 
previously published literature using a porcine model for stent related research. 
Hadaschik compared twenty pigs stented with Uriprene™ stents to 16 control stented 
pigs (Hadaschik et al., 2008). Pigs were sacrificed at 4 different time points, thus 
comparing 5 Uriprene™ stented pigs to 4 control pigs at any time point. In research of 
Keterolac-eluting stents, Chew et al. used 20 animals for each of the test groups, 
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sacrificing 4 animals in each group at 5 different time points (Chew et al., 2010a). 
Lumiaho et al compared an experimental stent to a control stent in 8 pigs, euthanized at 
two different time points, thus comparing 4 pigs at any time point (Lumiaho et al., 2011). 
Both Kallidonis et al. and Liatsikos et al used 10 pigs and inserted an experimental stent 
in one ureter and stented the contralateral ureter with a control stent. All pigs were 
euthanized at the same endpoint and acted as their own control (Kallidonis et al., 2011; 
Liatsikos et al., 2007). Chew et al in a subsequent Uriprene™ study compared 10 pigs 
stented unilaterally with an experimental stent to 6 pigs stented with a control stent all 
euthanized at the same time point (Chew et al., 2013).  
 
Figure 7: Flowchart of porcine experiment timeline 
We decided that having 6 animals in each group at each of two time points was optimal 
to collect sufficient bacteriological and histological data to allow for statistical analysis to 
identify significant differences between groups. In addition, we stented all animals 
bilaterally to increase the number of stents and urinary tract tissue we could analyze 
while using as few pigs as possible. 
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The surgeons could not be blinded to stent type during stent placement, though the 
veterinary technician team was blinded throughout the study. The laboratory technician 
and pathologist were both blinded during post-study sample analyses. 
 
2.2.1 Ureteral Stent Placement and Bacterial Challenge 
Pigs were anaesthetized using ketamine intramuscularly (IM) (11-22mg/kg body weight) 
in combination with one of the following: 1)Acepromazine (1 mg/kg body weight IM), 
2)Midazolam (0.5 mg/kg body weight IM) or 3)Xylazine (2.2mg/kg body weight IM). 
Once anesthetized, the animals were intubated for ventilation. The pigs were maintained 
during the procedures via inhalation isofluorane (1.5-5.0%). 
During anesthesia, pigs were positioned in supine position with the hindlegs strapped 
back to allow easy access to the genitalia. The genitalia were cleaned with two iodine 
scrubs followed by an alcohol prep. A rigid 14F pediatric cystoscope (Karl Storz, 
Mississauga, Canada) with a 30° downward angle lens (Karl Storz, Mississauga, Canada) 
was used to perform cystoscopy to identify the ureteral orifices of the pig. Sterile normal 
saline was used as irrigation fluid. With the cystoscope in the bladder, before performing 
any other steps of the procedure, a baseline urine sample was taken through the 
cystoscope. Once identified, the ureteral orifice was cannulated with a 0.035 inch 
hydrophilic guidewire (Terumo Corporation, Tokyo, Japan) under fluoroscopic guidance 
until the tip of the guidewire was identified in the renal pelvis of the kidney. As the 
porcine ureter is quite tortuous on occasion, contrast instillation was used through a 5Fr 
open ended Kumpé catheter (Cook Urological, Bloomington, IN, USA) when deemed 
necessary to outline the urinary tract. Once the hydrophilic guidewire was confirmed in 
the renal pelvis of the kidney, a 5Fr Kumpé catheter was advanced over the hydrophilic 
guidewire into the renal pelvis. At this point the hydrophilic guidewire was removed and 
exchanged for a 0.035 inch Bentson guidewire (Cook Urological, Bloomington, IN, 
USA). We subsequently placed the stent allocated to the animal over the guidewire, 
pushing it into place with the accompanying radiographically visible metal tip pusher 
device. The stent was placed under fluoroscopic guidance to confirm correct position of 
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the proximal curl of the stent in the renal pelvis and the distal curl of the stent in the 
bladder. This procedure was repeated for the contralateral ureter. When both ureteral 
stents were in situ, cystoscopy was repeated to identify both stent curls in the bladder and 
to subsequently empty the bladder through the cystoscope shaft. The bladder was then 
instilled through a working channel of the cystoscope with either 5ml of saline or 10E7 
CFU of the uropathogen E. coli GR12 in a 5 ml saline solution. One ml of saline was then 
used to flush the remaining bacteria inside of the working channel into the bladder, 
ensuring that the entire bacterial load was instilled in the bladder. The animal was then 
given the anti-inflammatory meloxicam (0.3 mg/kg SC) and analgesic buprenorphine 
(0.05 mg/kg SC or IM). After the procedure, anesthesia was reversed and all animals 
were recovered. This anesthesia regimen was suggested and performed by the 
veterinarian of the animal care facility. 
2.2.2 Sample Collection 
Urine and blood samples for culture and future cytokine analysis were collected at day 0, 
prior to the procedure during the same anesthesia and at day 1 and 3 under a short 
anesthesia for all animals. Animals allocated to the six day stent group were additionally 
anesthetized on day 6 for sample collection. Animals allocated to the 13 day stent groups 
had additional samples taken in the same manner on day 7, 10 and 13. The same 
anesthetic regimen as used during stent placement was used for the sample collections. 
Blood sample was taken by venipuncture in an ear vein after skin disinfection using an 
alcohol swab. Venipuncture was performed using a 16-18 gauge needle and collecting 
approximately 1-2ml venous blood according to SOP. Urine sample was taken aseptically 
by cystocentesis with a 16-18 gauge needle after sterile prepping the skin at puncture site 
with an alcohol swab. This procedure was preferred over taking a urine sample via the 
urethra to prevent perineal contamination of the sample. Upon completion of blood and 
urine collection, anesthesia was reversed.  
On the day of endpoint, pigs were euthanized following anesthesia for sample collection 
using 150 mg/kg intravenous sodium pentobarbital according to SOP. After euthanasia, 
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autopsy was performed to retrieve the implanted devices for analysis and to retrieve 
urinary tract tissue for histopathology evaluation: Kidney, ureter and bladder. A 
representative segment of kidney, ureter and bladder was excised separately for tissue 
bacterial count analysis. 
Histopathology specimens were submersed in formaldehyde and appropriately stored 
until analysis. All other collected samples and tissue were stored at -80°C following 
sample collection until time of analysis.  
2.3 Sample Analysis 
The urinary catheters from the rabbit study and the ureteral stents from the pig study were 
analysed for bacterial attachment, encrustation and via scanning electron microscopy. 
The urine samples were analysed for bacteria presence. The urinary pH of every urine 
sample taken was measured. The blood samples were taken for future cytokine analysis 
only. The representative segments of bladder, ureter and kidney that were taken post-
mortem were processed and analysed for tissue bacterial counts. The bladder, ureter and 
kidney that were resected whole organ during autopsy were processed and analysed 
microscopically for histopathology. The only vital sign collected was body temperature at 
day 0 and at study endpoint. 
2.3.1 Urine Culture 
The presence of E. coli in the collected urine samples was quantified by dilution plating 
on Lysogeny Broth (LB) agar (10 g/l tryptone, 5 g/l yeast extract, 10 g/l sodium chloride 
and 15 g/l granulated agar in Milli-Q H2O), a bacteria medium traditionally used for 
culturing E. coli. The agar plates were incubated at 37°C for 24 hours, after which 
colonies were counted to determine the CFU/ml of E. coli for each urine sample. Based 
on colony appearance and morphology under microscope, several non-E. coli colony 
types were identified which were also counted and recorded. Some, but not all of the 
other cultured species were later identified with DNA sequencing as Staphylococcus 
aureus, Enterococcus faecalis, Streptococcus suis and Lactobacillus species. 
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2.3.2 Device Bacterial Attachment 
For analysis of bacterial attachment, stents or urinary catheters collected post-mortem 
were cut into three one cm long segments: proximal, middle and distal segment. Each 
segment was placed in an Eppendorf tube and rinsed 3 times with sterile phosphate-
buffered saline (PBS) to remove unattached and loosely attached bacteria from the 
sample. The segments were then resuspended in 1mL PBS, sonicated for 20min at 50/60 
Hz (Branson 1200, Branson Ultrasonic Co., Danbury, CT, USA), and vortexed for 30 
seconds to detach the bacteria present on the segments into solution. Bacterial 
concentration was then determined through dilution plating on LB plates which were 
incubated for 24 hours at 37°C and the number of colonies recorded. Finally, the bacterial 
count was divided by the segment surface area to determine CFU/cm
2 
on the devices. 
 
2.3.3 Device Encrustation 
The amount of encrustation on the implanted devices was determined by evaluating a 
representative 2 cm segment. First, the 2cm segments were air-dried in open Eppendorf 
tubes for 24 hr. The segments were then weighed on an analytical scale with an accuracy 
of 0.1 mg (AC100 Analytical Balance, Mettler-Toledo, Mississauga, Canada) and the 
weights recorded. Next, encrustation from the outer surfaces were scraped off manually 
using a scalpel, and the devices were then washed vigorously with water via pipette-
mixing and vortexing to remove encrustation within the lumen and any remaining 
material on the outer surface. The segments were air-dried for 24 hours and weighed 
again. Encrustation was determined by subtracting the final segment weight from the 
initial weight and was recorded as mg/cm
2
. 
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2.3.4 Scanning Electron Microscopy and Energy Dispersive X-ray 
Spectroscopy  
Scanning electron microscopy and energy dispersive X-ray spectroscopy analysis 
(SEM/EDX) of the stents and catheters was performed on representative air-dried 
segments in the Division of Surface Science at Western University, London, Ontario. The 
samples were given a thin sputter deposited gold coating in order to alleviate charging 
during the SEM examination. SEM images and EDX graphs were obtained with a Hitachi 
S4500 Field emission SEM (Hitachi, Tokyo, Japan) using a 10 kV electron beam voltage 
with a Quartz XOne EDX system (Quartz Imaging Corp., Vancouver, BC, Canada). EDX 
can identify elements from Carbon to Uranium for elemental mapping. 
 
2.3.5 Tissue Bacterial Attachment and Internalization 
Representative tissue segments from bladder, kidney and ureter were analysed for tissue-
associated bacterial attachment and internalization. The tissue samples were weighed to 
0.1 mg accuracy (AC100 Analytical Balance, Mettler-Toledo, Mississauga, Canada) and 
transferred to 50 ml conical tubes. Tissue samples were first rinsed with sterile PBS to 
remove unattached and loosely attached bacteria. The samples were resuspended in 
varying volumes of PBS, depending on tissue size: rabbit bladder in 5ml PBS, rabbit 
ureter in 1ml PBS, rabbit kidney in 10ml PBS, and pig bladder, ureter and kidney all in 
20ml PBS. The tissue segments were subsequently homogenized at 30,000 rpm with a PT 
2100 Homogenizer (Kinematica, Littau, Switzerland) until a homogeneous suspension 
was established for every sample. The homogenate was then dilution plated, and plates 
were incubated for 24 hours at 37°C for bacterial quantification. The tissue-associated 
bacterial counts were measured in CFU/ml and then converted to CFU/mg. 
2.3.6 Histopathology 
Bladder and kidney samples were collected at necropsy and suspended in a 10% neutrally 
buffered formalin solution. The collected tissues were processed in a paraffin wax tissue 
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processor (Leica ASP3000, Leica Microsystems Inc., Concord, Canada) and 
subsequently embedded into paraffin wax blocks (Leica ECG 1150 HC, Leica 
Microsystems Inc., Concord, Canada) before sectioning. The samples were sectioned into 
5µm sections with a microtome (Microm HM335E Microtome, Thermo Fischer 
Scientific, Waltham, MA USA) and placed on microscopy slides. The slides were stained 
automatically with hematoxylin and eosin (Leica Autostainer XL, Leica Microsystems 
Inc., Concord, Canada). The sections were analysed with an Olympus BX 41 microscope 
(Olympus, Richmond Hill, Canada) by a veterinarian at Western University, London, 
Ontario, blinded to the stent groups. 
Kidney tissue was scored on urothelial inflammation, urothelial fibrosis, ulceration, 
mucinous metaplasia, squamous metaplasia, suburothelial hemorrhaging and 
suburothelial inflammation, scoring each as normal = 0, mild = 1, moderate = 2 or severe 
= 3. Scores were added up to a maximum of 21. Bladder tissue was scored on urothelial 
inflammation, urothelial fibrosis, ulceration, mucinous metaplasia, squamous metaplasia, 
suburothelial hemorrhaging, lamina propria fibrosis, lamina propria inflammation, 
muscle fibrosis and muscle integrity scoring each as normal = 0, mild = 1, moderate = 2 
or severe = 3. Scores were added up to a maximum of 30. 
To prevent score shifting and assure consistency in his scoring, the blinded pathologist 
checked his own scores afterwards for score variability and did not identify any scoring 
variability. 
 
2.4 Statistical Analysis 
The primary outcomes in this analysis are stent encrustation and urinary tract infection 
with stent coating considered as an independent variable. 
For categorical variables such as the qualitative outcomes of the urine culture (positive or 
negative), Chi Square and Fisher’s exact test were used. Post-hoc between group analysis 
was likewise performed with a two-sided Fisher’s exact. 
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For continuous variables such as the quantitative outcomes of the urine cultures, device 
bacterial attachment, encrustation and bacterial tissue counts, ANOVA was used with the 
post-hoc Dunnett’s T-test to control for multiple group comparison.  
Because of the high CFU counts in our data and the relatively low sample size, we could 
expect a non-normal distribution of the data (Figure 8). The red line in this graph is a 
normal distribution graph and is quite skewed here, indicating that the data doesn’t follow 
a normal distribution. The data is much better fitted under the green line, which shows 
the exponential distribution. To have our CFU data follow a normal distribution, we log10 
transformed our data for statistical analysis and transformed them back afterwards (Bland 
and Altman, 1996; Olsen, 2014). The lowest detectable level of infection is 100 CFU/ml. 
For some endpoints, some animals did not have a detectable infection, resulting in a 0 
value for CFU/ml. As zero values cannot be log transformed, a value of 1 was added to 
the data so that log(0+1)=0 and no datapoints are lost for analysis. 
Shapiro-Wilk test was performed to explore the normal distribution of data. If despite 
log-transforming, the data did not follow a normal distribution, non-parametric tests 
where applied such as Mann-Whitney-U and Kruskal-Wallis where appropriate. 
Homogeneity of variance of the data was ascertained with Levene’s test. Welch’s 
ANOVA was performed on the data where Levene’s test was statistically significant, 
indicating heteroscedasticity. We used Games-Howell for post-hoc analysis after Welch’s 
ANOVA for multiple group comparison instead of Dunnett’s T-test, as Games-Howell is 
more robust for heteroscedastic data. 
Statistical analysis was performed using SPSS 22 software (IBM Corp., Armonk, NY, 
USA). Significance was assessed at P<0.05. 
Although the data of these in vivo experiments was log transformed for statistical 
analysis, as is suggested in the literature, statistical analysis was equally performed on the 
raw data. Interestingly so, this did not influence the statement towards the null-hypothesis 
in any of our results. 
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Figure 8: Histogram of the raw data and distribution of raw data of pigs urine samples on Day 1 in 
CFU/ml. The red line indicates the normal distribution, while the green line indicates a non-normal 
distribution. 
 
2.5 In vitro Assessment of Catheter Coatings 
We aimed to identify whether or not the coatings retained their efficiency several months 
after coating the devices by performing in vitro analysis on the coated and uncoated 
stents we had received prior to performing the animal study. 
For the in vitro experiments, we exposed the stent segments to seven different 
uropathogenic bacterial strains (E. coli, E. faecalis, K. pneumonia, P. mirabilis, S. 
saprophyticus, S. epidermidis and P. aeruginosae) for the purpose of evaluating the anti-
attachment and anti-bacterial capacity. Bacterial cultures were grown for 16 hours in LB 
at 37°C, diluted 1/100, and incubated for three hours (E. coli, E. faecalis, K. pneumonia 
and P. mirabilis) or five hours (S. saprophyticus, S. epidermidis and P. aeruginosae), 
depending on the growth rate of the species. Cultures were then diluted to reach a final 
concentration of 5x10
5
 CFU/mL. Bacterial strains used for the in vitro assessment assay 
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included one strain from each of 7 clinically relevant uropathogenic bacterial species, 
including Escherichia coli GR-12 (pyelonephritis isolate)
 
(Hagberg et al., 1983), 
Staphylococcus saprophyticus ATCC 15305 (clinical urine isolate) (Erdeljan et al., 
2012), Proteus mirabilis 296 (catheter isolate) (Watterson et al., 2003b), Pseudomonas 
aeruginosa AK-1 (UTI isolate) (Reid et al., 1994), Klebsiella pneumoniae 280 (UTI 
isolate) (Wignall et al., 2008), Enterococcus faecalis 1131 (UTI isolate) (Smeianov et al., 
2000), and Staphylococcus epidermidis 3399 (clinical skin isolate) (Saldarriaga 
Fernández et al., 2007). All strains were grown and maintained in LB and on LB agar 
plates at 37°C in ambient air. To prevent swarming of P. mirabilis 296, this strain was 
grown on non-swarming agar (NSA [10g tryptone, 5g yeast extract, 0.4g sodium chloride 
and 20g agar per L]). 
Uncoated and coated stents were cut into 1 cm segments and placed in 24-well non-tissue 
culture plates (BD Falcon). We subsequently transferred 1 mL aliquots of the cultures to 
the wells containing the stent segments. The plates were incubated for 24 hours at 37°C 
under shaking conditions to mimic urinary flow and to keep the devices uniformly 
exposed to the bacteria. 
Bacterial attachment was quantified as previously described in section 3.3.2. For 
quantifying the concentrations of planktonic bacteria, cultures from each well were 
transferred directly to 96-well non-tissue culture plates (BD Falcon) and dilution plated. 
These experiments were carried out three times in triplicate. The results generated are the 
means of each triplicate. Figure 9 schematically demonstrates the in vitro experiments 
performed. 
As previously mentioned, the raw data were log transformed before performing statistical 
analysis. We performed ANOVA with post-hoc Dunnett’s T-test on both planktonic and 
bacterial attachment data. 
 
 55 
 
 
Figure 9: Schematic representation of in vitro experiment 
 56 
 
Chapter 3  
3 Results 
After sample collection, all samples were analyzed as described. Complete data was 
available for urine culture, bacterial attachment, encrustation and tissue bacterial count 
analysis of both rabbit and pig studies. Histopathology was analyzed for the porcine 
study. SEM and EDX was performed on stent and catheter segments from both studies. 
3.1 Results Rabbit Study 
3.1.1 Urine Culture 
In contrast to humans, there is no definition of what amount of CFU constitutes 
bacteriuria or a urinary tract infection in rabbits. Additionally it was not feasible to assess 
symptoms of a UTI such as frequency, pollakiuria or dysuria. We therefore opted to 
identify the number of rabbits with a positive culture without a CFU cutoff value. 
Results on the urine culture analysis are available in Table 1. We have some missing data 
for the E. coli CFU counts. We were unable to obtain a urine sample on 3 occasions and 
we could not reliably count the E. coli CFU in 6 samples due to Proteus mirabilis 
swarming in the petri dish. There was no statistical difference in the number of animals 
having a positive E. coli sample for Days 1, 3 and 5. Fisher’s exact test for data on day 7 
shows a tendency towards significance with a P-value of 0.066. When comparing the 
results between groups with a two-sided Fisher’s exact test, we see that there are 
statistically fewer rabbits with a positive urine culture in the coating A group compared to 
the control group with a P-value of 0.036. Group B is not significantly different from the 
control group (P= 0.193) (Figure 10). 
When evaluating the degree of infection between groups by comparing the log(x+1) 
transformed CFU data between groups at any time point, we could not identify any 
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significant differences between groups at any given time point indicating that the groups 
don’t have a significantly different degree of infection. As the data does not follow a 
normal distribution, Kruskal-Wallis was performed on this data. There were no other 
statistical differences between groups at any other time points (Figure 11). 
 
  Uncoated Coating A Coating B P-value 
Day 1 #infected/total 9/12 8/10 8/11 1* 
Mean (SD) 2.29E6 (5.06E6) 9.04E5 (2.71E6) 6.74E6 (1.79E 0.837
$
 
Day 3 #infected/total 10/12 9/10 7/12 0.216* 
Mean (SD) 7.70E6 (2.13E7) 4.72E5 (1.30E6) 4.98E5 (1.06E7) 0.950
$
 
Day 5 #infected/total 11/12 7/10 6/11 0.138* 
Mean (SD) 1.59E6 (3.56E6) 1.77E6 (5.35E6) 2.01E7 (5.35E7) 0.707
$
 
Day 7 #infected/total 10/12 4/11 6/12 0.066* 
Mean (SD) 3.85E6 (8.08E6) 2.28E6 (6.89E6) 4.03E6 (1.16E7) 0.205
$
 
Table 1: Rabbits with positive urine sample with the means and standard deviations of the CFU/mL 
of E. coli at the different time points. *= Fisher’s exact test, $= Kruskal-Wallis 
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Figure 10: Diagram showing proportion of animals with a positive urine culture at the different time points 
in %. * P-value = 0.036 
 
Figure 11: Bar graph showing means and standard deviations of CFU/ml for each of the groups at every 
time point.  
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When reading out the urine culture plates, we did not only identify E. coli on the agar. As 
mentioned before, some samples even had Proteus mirabilis swarming so that we could 
not reliable read out the E. coli count. Other bacteria identified were Staphylococcus 
aureus and Enterococcus faecalis. Some colonies observed however could not be 
identified and were thus grouped according to their appearance. 
Fisher’s Exact test could not identify a difference in number of rabbits having other 
bacteria cultured in their urine samples at any of the time points. Interestingly, we did 
identify an increasing number of other bacterial species present in the urine samples with 
time. Whereas on day 1 only 2 rabbits had any of the other bacterial species present in the 
urine, 22 rabbits had one or more of the other species present in the urine sample by 
endpoint. For analytical purposes, the presence of any of the other identified bacteria was 
grouped to form the ‘non E. coli’ infection group. No differences between groups were 
demonstrated with Fisher’s Exact test. ANOVA and where applicable Kruskal-Wallis 
could not demonstrate a difference between groups for the degree of infection with other 
bacteria. Once again, no differences were unveiled between coating groups with 
statistical analysis. 
 
3.1.2 Device Bacterial Attachment 
For catheter bacterial attachment, the number of CFU/ml of E. coli were measured and 
converted to CFU/cm². Proximal, middle and distal segment of the catheter represent 
different places in the urinary tract. The proximal segment of the catheter was present in 
the bladder, whereas the middle segment was present in the urethra. The distal segment 
was outside of the urethra and generally in touch with the skin and often soiled with 
rabbit’s excretions. 
In the first group of 12 animals tested, we had an issue with migration of the catheters out 
of the bladder. In some animals the catheters had disappeared. One animal of the 
uncoated group and one animal of the Coating A group had a missing catheter at 
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endpoint. They were retrieved at autopsy in the stomach. We therefore do not have 
bacterial attachment numbers for these catheters. We did not analyze the distal part of the 
catheters of the first 4 animals in every group because of the assumption that these were 
not representative of any infection in the urinary tract of the animal. We collected and 
analyzed the distal segments of all subsequent animals. 
When comparing the amount of catheters that had E. coli attached to the surface, there 
were no significant differences between groups (3X2 contingency table with Fisher’s 
Exact test, P= ). When performing ANOVA after log(x+1) transforming, similarly no 
statistical differences could be demonstrated between groups (Figure 12). 
Data reported in Table 2 are means and standard deviations of E. coli CFU/cm² and the 
number of catheters with bacterial attachments. 
 
Figure 12: Bar chart showing means and standard deviations of E. coli attachment on the devices in 
CFU/cm².  
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     Uncoated     Coating A     Coating B P-Value 
Proximal # infected/total 4/10 6/11 5/12 0.756* 
Mean (SD) 1.15E5 (3.17E5) 3.25E4 (7.54E4) 3.83E6 (1.26E7) 0.950
†
 
Middle # infected/total 6/10 2/11 3/12 0.138* 
Mean (SD) 1.48E4 (4.26E4)   1.32E4 (3.55E4)   2.43E6 (5.70E6)   0.474
†
 
Distal # infected/total 2/8 1/8 2/8 0.705* 
Mean (SD) 2.52E4 (7.10E4) 2.75E1 (7.78E1) 7.17E4 (2.03E5) 0.620
†
 
Table 2: CFU of E. coli bacterial attachment on the catheter segments. *= Fisher’s exact test. †= 
ANOVA. 
 
When comparing the bacterial attachment of the rabbits that had a positive E. coli urine 
sample on day 7 compared to the ones that did not, we see that the infected animals have 
more bacterial attachment than the uninfected rabbits. Data was log(x+1) transformed for 
the analysis and did not show a normal distribution. Mann-Whitney-U test identified the 
proximal and middle segments of the catheter to have significantly fewer bacterial 
attachment in the uninfected animals (P-values 0.027 and 0.005 respectively). None of 
the uninfected rabbits had any bacterial attachment on the middle segment (Figure 13). 
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Figure 13: E. coli attachment in CFU/cm² for proximal, middle and distal segment in animals with or 
without a planktonic E. coli infection . *: P=0.027; **: P=0.005 
When repeating this analysis for all the different bacterial species cultured from the urine 
samples, similar results were obtained with uninfected rabbits having significantly less 
bacterial attachment on the catheter segments. 
 
3.1.3 Encrustation 
We found encrustations present on every urinary catheter inserted in the rabbits. The 
encrustations were quantified as described in previous chapter. The uncoated group had 
on average 2.69 mg of encrustations per cm², ranging from 0.14 to 6.73. The catheters 
from coating A and coating B had on average 4.74 and 7.22 mg of encrustations per cm² 
respectively, ranging from 2.39 to 11.08 and from 1.48 to 16.9 mg/cm² respectively. 
Statistical analysis comparing the amount of encrustations in the three groups with 
ANOVA produced a P-value of 0.016 demonstrating a significant difference between 
groups. As Levene’s test was significant indicating heteroscedasticity within this 
normally distributed data (Shapiro-Wilk was not significant), we performed Welch’s 
ANOVA with Games-Howell post-hoc analysis. There is a statistically significant 
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difference between groups with a P-value of 0.022 for all groups comparison. Games-
Howell shows that the catheters coated with coating B had significantly more 
encrustations on the surface than the uncoated catheters (P=0.027). (Figure 14). 
 
As Pechey (Pechey et al., 2009) et al had identified an inverse correlation of encrustations 
with infections, we compared the encrustations of infected rabbits to non-infected rabbits 
with ANOVA. For this purpose, infection was defined as having a positive E. coli urine 
sample on the day of catheter extraction, day 7. The rabbits that had an E. coli positive 
urine culture on day 7 had on average 3.79 mg/cm² of encrustations on the catheter 
whereas rabbits with no E. coli in the urine sample on day 7 had an average of 6.93 
mg/cm² encrustations. The infected group had statistically fewer encrustations than the 
non-infected group (P= 0.022), thus corroborating Pechey’s results (Figure 15). The 
mean and standard deviations of the encrustations in each of the groups, are shown in 
Table 3. 
 
 
Figure 14: Means and standard deviations of Encrustations in mg/cm² for the different catheter groups.  
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As the presence of an E. coli infection seems to influence the amount of encrustation 
inversely, we wanted to verify this for any of the other bacteria identified in some of the 
urine samples. When considering each of the bacterial species separately, comparison of 
the amount of encrustations in the infected or uninfected animals showed no statistical 
difference. However, when grouping these as ‘non-E. coli’ infection, we interestingly 
demonstrated that the rabbits that had a non-E. coli infection on day 7 had more 
encrustations than the non-infected animals (P-value of 0.008 with Welch’s ANOVA), 
which is the contrary of what we had identified in the E. coli infected animals (Figure 
15). 
 
 
Figure 15: Encrustations in mg/cm² grouped in rabbits with or without a positive urine sample for E. coli 
or non-E. coli bacteria 
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 Control Coating A Coating B P-value 
Encrustations Mean (SD) 2.69 (2.30) 4.74 (2.32) 7.22 (4.81) 0.022$ 
 UTI No UTI P-value 
E. coli 3.79 (3.06) 6.93 (4.31) 0.022* 
Non E. coli 6.40 (4.24) 3.13 (2.25) 0.008$ 
Table 3: Encrustations on the catheters measured in mg/cm². $= Welch’s ANOVA, *= ANOVA 
 
Considering that several animals had more than one bacterial species identified on urine 
culture and considering the opposite effect of E. coli vs. non-E. coli infection, we aimed 
to uncover the influence of presence of E. coli only, non-E. coli only or both E. coli and 
non-E. coli in urine on the degree of encrustations on the catheter surface with ANOVA. 
As expected, the rabbits that had only E. coli present in their urine sample on day 5 
(18/33 rabbits) and day 7 (12/35 rabbits), had significantly less encrustations than the 
other rabbits (P= 0.006 and 0.024 respectively). Conversely, the rabbits that had only 
non-E. coli bacterial species present in their urine sample on day 7 (14/35), had 
significantly more encrustations than the other rabbits (P= 0.012). The opposite effects of 
both in mind, we analyzed the data for rabbits that had both E. coli and any of the other 
bacterial species present in their urine sample. No significant differences were identified 
and for the day 7 data, P-value was 0.944. 
As mentioned previously in this manuscript, the deposition of encrustations on a surface 
submersed in urine is dependent of multiple factors, among which the urinary pH. We 
therefore aimed to verify pH as an influence on the amount of encrustations. 
Unfortunately, the urinary pH was not measured for 5 of the 36 rabbits: 2 in the uncoated 
and Coating A group and 1 in the coating B group. We could not identify a direct strong 
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correlation between encrustations and urinary pH at any time point. As E. coli seems to 
have a reducing influence on encrustations, we compared the E. coli only rabbits to the 
other rabbits for pH. Mann-Whitney-U (ANOVA could not be performed due to non-
normal distribution) indicates that there is indeed a significant difference between the two 
groups with the E. coli only animals having a significantly lower pH on day 7 compared 
to the other rabbits in the experiment (mean +/- SD: 7.7 +/-1.2 vs. 8.7 +/-0.4; P-
value=0.031). 
 
3.1.4 Scanning Electron Microscopy and Energy Dispersive X-ray 
Spectroscopy (SEM & EDX) 
SEM pictures were taken from an uncoated polyurethane control catheter to establish the 
baseline appearance of an uncoated catheter (Figure 16) and subsequently from the 
coated catheters (Figure 17). The main difference between the two coatings is the density 
of S-095: the density of S-095 in Coating B is 5 times higher than in Coating A. This 
difference in density is apparent on the SEM Figures 17 A and C, showing catheter 
segments coated with Coating A and B respectively. Both pictures are taken at the same 
magnification but the crater-like structures are smaller and more numerous in Figure 17 
C (Coating B). 
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Figure 16: SEM pictures at 1000 x (A) and 5000 x (B) magnification of an uncoated polyurethane catheter 
before implantation. 
 
 
Figure 17: SEM pictures at 1000 x (A/C) and 5000 x (B/D) magnification of catheters coated with Coating 
A (A/B) and catheters coated with Coating B (C/D). The white spots represent silver particles in the 
coating. 
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The S-095 coatings contain Barium and Sulfur ions. Due to the capabilities of full 
spectrum imaging with the elemental mapping, we can select single elements for map 
creation. The blue and yellow pictures in Figure 18 depict the mapped content of Barium 
and Sulfur on a coated stent. These pictures show that the distribution of S-095 is quite 
homogeneous on the stent surface. The green picture demonstrates the presence of Silver 
on the coating. 
 
 
Figure 18: SEM pictures of a coated device. The pictures in blue and yellow represent the presence of 
Barium and Sulfur on the picture. The picture in green represents the presence of Silver in the coating. 
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We subsequently analyzed the catheters from animals with and without E. coli infection 
for analysis of attached bacteria and encrustations on the catheters. 
Figure 19 shows a SEM of a catheter segment of a rabbit catheterized with a Coating A 
catheter that did not have an E. coli infection on day 7 nor any E. coli attached to the 
surface of the catheter. There were other bacteria present, which unfortunately could not 
be identified. This catheter had 3.96mg/cm² of encrustations on the surface. The asterisk 
shows a calcium oxalate crystal on the surface. The picture in Figure 20 is taken from the 
same catheter segment. Electron dispersive X-Ray Spectroscopy was performed 
demonstrating a spectrum consistent with calcium oxalate dihydrate (C2H4Ca06).  
 
Figure 19: A: SEM picture of an encrusted catheter of a rabbit in Coating A group at 1000x magnification. 
B: close-up of same catheter at 5000x magnification. *: Calcium Oxalate crystal. 
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Figure 20: SEM picture at 5000X magnification of the same catheter as in Figure 19. Upper right shows 
EDX of the crystal and lower right shows EDX of the micro-organism on the catheter. 
 
EDX of the encrustations of a rabbit having an E. coli infection and E. coli attachments 
on the catheter surface appears to be quite different as is apparent in Figure 21. In 
contrast to the encrustations on the catheters of non E. coli-infected rabbits (Figure 20), 
the catheters of E. coli infected rabbits do not show any calcium oxalate dihydrate. Two 
different shapes of encrustations can be identified. The large crystalline mass shows high 
peaks of Oxygen, Magnesium and Phosphate in its spectrum, which correlates best with 
struvite (NH4MgPO4·6H2O). The spectrum of the small spheres on the other hand show 
high peaks of Oxygen, Calcium and Phosphate. Both EDX spectrum and the SEM 
appearance are consistent with hydroxyapatite (Ca10(PO4)6(OH)2). 
In contrast to analysis of bacterial attachment, we could not identify any E. coli on any of 
the segments that were supposed to have E. coli attached to the catheter surface. 
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Figure 21: SEM and EDX of encrustations on a catheter that had E. coli attachment on the surface 
 
3.1.5 Tissue Bacterial Counts 
Comparable to the urine culture and bacterial attachment data, we identified multiple 
bacterial species, other than the inoculated E. coli GR12, inside of or attached to the 
analyzed tissue. Because of the low bacterial counts for every individual non-E. coli 
species, these were combined as ‘non-E. coli bacteria’ number of CFU/mg. 
The data on number of rabbits having E. coli in bladder, ureter or kidney tissue in each of 
the groups, are demonstrated in Table 4. Statistical analysis with Fisher’s Exact Test 
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identified that there was a trend towards a difference in infection rate in the bladders 
between the groups (P=0.061). Two-sided Fisher’s exact test for between group 
comparison, showed significantly fewer rabbits in the Coating A group having E. coli 
positive bladders compared to the control group (P=0.039). Three of all the ureters 
analyzed demonstrated E. coli on culture. No ureters from the uncoated group had any E. 
coli after culturing, whereas E. coli was cultured from one ureter from a coating A rabbit 
(15.9 CFU/mg) and from ureters from two coating B group rabbits (8100 and 190 
CFU/mg respectively). We could not identify any E. coli in any of the kidneys. ANOVA 
on the log(x+1) transformed CFU data in the bladder tissue demonstrated no statistical 
difference between groups (P= 0.325). When comparing the degree of bacterial counts 
adherent to or within the bladder tissue of infected vs. uninfected rabbits on day 7 with 
Welch’s ANOVA (as Levene’s test indicated heterogeneity of variance), the uninfected 
animals have significantly lower CFU counts than the infected rabbits (P<0.001 for E. 
coli). When considering any of the other bacterial species present in the tissue, the groups 
were not statistically different for any of the analyzed tissues. 
 Uncoated Coating A Coating B P-value 
Bladder 9/12 3/12 6/12 0.061 
Ureter 0/12 1/12 2/12 0.758 
Kidney 0/12 0/12 0/12 1 
Table 4: Number of rabbits that had E. coli cultured from the tissue samples. 
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3.2 Results Pig Study 
3.2.1 Urine Culture 
We were not able to collect a urine sample from one pig in the coating A group on day 3. 
All the other samples were obtained as per protocol. 
To identify the influence of the placement and presence of the devices, we compared the 
UnS group to the UnEC group for presence of UTI and number of CFUs of the different 
bacteria identified at all time points. Eight of the 12 pigs in the UnS group developed a 
urinary tract infection by day 1, defined as presence of any E. coli in the urine sample. As 
expected, 11 of the 12 pigs in the UnEC group had developed an infection. In the short-
term group, 5 out of 6 of the UnEC pigs had a UTI at endpoint compared to 4 out of 6 in 
the UnS group at endpoint. In the long-term group, all pigs in the UnEC group had a UTI 
compared to 4 out of 6 in the UnS group. Two-sided Fisher’s exact test could not 
demonstrate a significant difference between the two groups at any time point. 
The degree of infection was compared with ANOVA on the log(x+1) transformed data. 
Shapiro-Wilk test showed a significant P-value for the log transformed data, rejecting 
normal distribution. As such, we performed Kruskal-Wallis as a non-parametric test for 
continuous variables on the transformed data which resulted in no statistical difference 
among groups at any time point (Figure 22). All data is demonstrated in Table 5. 
 
Statistical analysis was repeated for all non-E. coli bacteria that were identified. Shapiro-
Wilk test demonstrated the data to be non-normally distributed. We therefore applied 
Kruskal-Wallis tests with post-hoc between group analysis where applicable, which in 
turn could not identify any significant difference among groups. 
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  Uncoated 
Saline 
Uncoated EC Coating A Coating B P-value 
Day 1 #infected/total 8/12 11/12 12/12 10/12 0.174* 
Mean (SD) 2.15E7 
(4.40E7) 
1.58E7 
(5.06E7) 
4.88E6 
(1.05E7) 
1.96E6 
(3.15E6) 
0.862
$
 
Day 3 #infected/total 8/12 10/12 10/11 11/12 0.473* 
Mean (SD) 9.31E7 
(2.34E8) 
1.33E8 
(4.31E8) 
3.13E7 
(6.05E7) 
8.07E6 
(9.57E6) 
0.879
$
 
Day 6 #infected/total 4/6 5/6 6/6 6/6 0.573* 
Mean (SD) 4.61E6 
(7.65E6) 
1.35E7 
(3.26E7) 
1.72E7 
(4.06E7) 
9.43E5 
(7.91E5) 
0.710
$
 
Day 7 #infected/total 5/6 5/6 6/6 6/6 1.00* 
Mean (SD) 2.98E7 
(6.39E) 
8.48E6 
(1.32E7) 
8.64E6 
(2.03E7) 
4.82E6 
(6.44E6) 
0.733
$
 
Day 10 #infected/total 4/6 6/6 6/6 6/6 0.217* 
Mean (SD) 1.30E7 
(1.41E7) 
1.53E7 
(3.02E7) 
6.08E6 
(9.01E6) 
7.22E6 
(1.52E7) 
0.987
$
 
Day 13 #infected/total 4/6 6/6 6/6 6/6 0.217* 
Mean (SD) 2.11E7 
(3.36E7) 
4.03E5 
(3.72E5) 
5.88E6 
(1.05E7) 
3.99E6 
(6.73E6) 
0.451
$
 
Table 5: Number of pigs with E. coli infection and severity of infection in CFU/ml. * = Fisher exact test, 
$= Kruskal-Wallis on log(x+1). 
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Figure 22: Means and standard deviations of urinary planktonic E. coli CFU/ml. 
 
3.2.2 Bacterial Attachment 
For catheter bacterial attachment, the number of CFU/ml of E. coli were calculated and 
converted to CFU/cm². Proximal, middle and distal segment represent different places in 
the urinary tract. The proximal segment of the stent was present in the kidney, the middle 
segment in the ureter and the distal segment in the bladder. 
One pig in the uncoated stent saline challenged group did not get a left stent implanted 
due to technical difficulty of the procedure. 
Due to time constraints, the stents collected from one group of 6 pigs that all had surgery 
on the same date were not immediately processed for analysis after autopsy but kept in 
storage at -80°C until we were able to process them. After processing, these stent 
segments showed to have no to very low attachment numbers. To identify whether or not 
these data influenced the outcomes of statistical analysis, sensitivity analysis was 
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Data was log transformed to fit normal distribution. Shapiro-Wilk test confirmed all log 
transformed data for this analysis to follow a normal distribution. Levene’s test showed 
the data to be homoscedastic. 
No significant differences in bacterial attachment could be identified with statistical 
analysis. The amount of E. coli attached to uncoated or coated catheters was similar 
between groups at any of the stent segments. P-values obtained after post-hoc analysis 
with Dunnett’s T-test are approaching or equaling 1, emphasizing the similarity between 
groups. Means and standard deviations of CFU/cm² of bacterial attachment on the stent 
segments are shown in Table 6 a and b. 
When evaluating the number of stents that had bacterial attachments in the different 
groups, no statistical difference could be identified with Fisher’s exact test. Both in the 6 
days and the 13 days indwelling time group, no statistical difference could be 
demonstrated. The number of stents that had attachments seems however smaller in the 
coating B group that had stents for 13 days, which is somewhat counterintuitive 
considering the rest of the data. 
For sensitivity analysis, data was ignored from 1 pig in the UnS, 13 day group, 1 pig from 
the coating A 13 day group and 4 pigs from the coating B 13 day group. This may 
explain why the number of stent segments displaying attached bacteria seemed so low in 
the coating B group of the 13 days stented pigs. 
After performing sensitivity analysis we can conclude that omitting the results did not 
substantially change any of the results as the null hypothesis was still retained. 
Data from left sided stents were compared to right sided stents and were found to be 
statistically not significantly different. To increase numbers for statistical analysis, we 
therefore analyzed all attachment data regardless of stent side. All analyses were repeated 
including the sensitivity analysis. No significant difference between groups could be 
identified with Fisher’s exact test or ANOVA. Post-hoc analysis could not demonstrate 
any differences in the between-group analyses. 
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 Uncoated 
Saline 
Uncoated EC Coating A Coating B P-value P-value b 
Prox Right 
Mean (SD) 
1.20E5 
(2.82E5) 
8.40E4 
(2.25E5) 
4.79E4 
(7.43E4) 
4.54E4 
(8.01E4) 
0.815* 0.580* 
#infected/total 8/12 10/12 10/12 10/12 0.807
†
 0.507
†
 
6 days 4/6 5/6 5/6 6/6 0.878
†
 0.878
†
 
13 days 4/6 5/6 5/6 4/6 1.000
†
 1.000
†
 
Mid right 
Mean (SD) 
1.20E7 
(4.13E7) 
1.21E5 
(4.03E5) 
1.37E5 
(2.31E5) 
7.90E4 
(2.35E5) 
0.593* 0.883* 
#infected/total 7/12 10/12 9/12 6/12 0.359
†
 0.604
†
 
6 days 3/6 5/6 5/6 4/6 0.766
†
 0.766
†
 
13 days 4/6 5/6 4/6 2/6 0.463
†
 0.877
†
 
Distal right 
Mean (SD) 
8.17E4 
(1.99E5) 
2.46E5 
(6.93E5) 
4.03E5 
(1.26E6) 
2.33E5 
(7.62E5) 
0.673* 0.836* 
#infected/total 7/12 9/12 9/12 7/12 0.746
†
 0.902
†
 
6 days 3/6 4/6 5/6 5/6 0.766
†
 0.766
†
 
13 days 4/6 5/6 4/6 2/6 0.463
†
 0.877
†
 
Table 6A: Proportions of pigs with bacterial attachment on the right-sided stent and CFU/cm² of bacterial 
attachment on right stent segments. *=ANOVA, 
†= Fisher’s Exact 
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 Uncoated 
Saline 
Uncoated EC Coating A Coating B P-value P-value b 
Prox left 
Mean (SD) 
3.23E4 
(8.00E4) 
1.03E5 
(2.22E5) 
1.70E5 
(5.39E5) 
2.34E5 
(7.07E5) 
0.448* 0.580* 
#infected/total 5/11 9/12 7/12 5/12 0.366
†
 0.699
†
 
6 days 2/5 4/6 3/6 4/6 0.843
†
 0.843
†
 
13 days 3/6 5/6 4/6 1/6 0.180
†
 0.737
†
 
Mid left 
Mean (SD) 
1.93E3 
(5.58E3) 
8.71E4 
(2.63E5) 
5.29E4 
(1.28E5) 
4.70E4 
(8.07E4) 
0.541* 0.318* 
#infected/total 5/11 7/12 8/12 6/12 0.818
†
 0.650
†
 
6 days 2/5 4/6 4/6 5/6 0.573
†
 0.573
†
 
13 days 3/6 3/6 4/6 1/6 0.483
†
 0.906
†
 
Distal left 
Mean (SD) 
8.55E4 
(2.16E5) 
4.06E5 
(1.04E6) 
3.04E4 
(4.89E4) 
2.888E5 
(6.26E5) 
0.690* 0.482* 
#infected/total 6/11 9/12 9/12 7/12 0.701
†
 0.600
†
 
6 days 2/5 4/6 5/6 5/6 0.458
† 
0.458
†
 
13 days 4/5 5/6 4/6 2/6 0.463
†
 1.000
†
 
Table 7B: Proportions of pigs with bacterial attachment on the left-sided stent and CFU/cm² of bacterial 
attachment on left stent segments. *=ANOVA, 
†
= Fisher’s Exact 
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3.2.3 Encrustation 
In contrast to the rabbits, no stents retrieved from the pigs were found to have any 
encrustations on the surface or in the lumen, although virtually all the pigs had positive 
urine cultures at endpoint.  
 
3.2.4 SEM/EDX 
Scanning electron microscopy with energy dispersive X-Ray Spectroscopy was 
performed to identify if there were any attachments or encrustations on the stents after 
indwelling time. As previously mentioned, no encrustations have been found on the stents 
retrieved from the pigs and the bacterial attachment numbers on the stent surface are 
fairly low and are not statistically different among groups. With SEM/EDX we aimed to 
confirm these results and indeed, no encrustations could be detected with SEM.  
Figure 23 is an SEM picture with EDX graph taken from a pig stented for 6 days with an 
uncoated stent that had an E. coli infection and E. coli on surface attachments. Although 
we expected to find bacteria on the surface, we could not find any during SEM analysis. 
EDX shows no organic material present on the stent. In fact, the stent segment shown in 
the picture looks almost untouched by the 6 days indwelling in a urinary environment. 
 
Figure 23: SEM at 3000x magnification of stent retrieved from 6 days stented pig. 
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3.2.5 Tissue Bacterial Counts 
All tissues collected at necropsy were processed and analyzed. As described previously, 
tissue infection numbers were reported in CFU/mg of tissue. Again, ANOVA showed the 
groups to have no statistical differences for any of the measured CFU/mg of E. coli in 
tissue samples. Analysis was repeated for other species identified in the tissue and 
similarly could not demonstrate statistical differences between groups. The means and 
standard deviations of the CFU/mg of E. coli in the tissue samples is available in Table 7 
 
 Uncoated Saline Uncoated EC Coating A Coating B P-value 
L Kidney 
Mean (SD) 
1.11E2 (2.33E2) 2.52E2 (6.06E2) 1.09E3 (2.78E3) 6.85E2 (1.77E3) 0.524 
R Kidney 
Mean (SD 
1.82E2 (2.78E2) 5.13E2 (1.57E3) 8.38E2 (1.96E3) 3.35E2 (4.88E2) 0.634 
L Ureter 
Mean (SD 
7.64E2 (2.37E3) 3.39E3 (1.05E4) 3.22E3 (1.00E4) 2.21E3 (5.28E3) 0.281 
R Ureter 
Mean (SD 
1.40E3 (4.23E3) 5.33E2 (1.03E3) 2.15E3 (5.02E3) 6.19E2 (9.08E2) 0.298 
Bladder 
Mean (SD 
1.32E2 (2.53E2) 1.25E3 (4.14E3) 4.65E2 (1.00E3) 3.14E2 (6.14E2) 0.556 
Table 8: Degree of E. coli infection inside of or attached to the tissue in CFU/mg. 
 
When comparing results from the 6 day stented pigs to the 13 days stented pigs, no 
significant differences were identified. We likewise did not find any differences between 
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the left sided tissue counts and the right sided tissue counts. As these results were 
comparable, we decided to group both left and right sided results to increase power of our 
statistical analysis. Once again however, no statistical differences were found between 
groups for bacterial tissue counts, demonstrating that the stent coating had no influence 
on tissue infection numbers. 
 
3.2.6 Histopathology 
All the tissue from the pigs from the short-term stented group were processed for 
histopathology analysis. The pathologist was able to accurately read out the slides for all 
of the samples. As previously indicated he frequently reassessed previously scored slides 
to prevent score shifting and observed consistency in scoring. 
When comparing the scores for all the previously mentioned histopathology changes 
between coating groups with Fisher’s exact test, it appears that there are significantly 
more pigs from the uncoated saline challenge group that have a higher degree of 
mucinous metaplasia in the right-sided bladder samples compared to the control group. P-
value for the entire comparison was 0.035 and between group analysis identified a 
significant difference for uncoated saline challenge vs. uncoated E. coli challenge with a 
P-value of 0.03. The samples from the coating A and B group were not significantly 
different from the control group. Regression analysis could not point out any 
confounding factors influencing the mucinous metaplasia after controlling for degree of 
planktonic infection, amount of attached CFU/cm² on the stents, operating time and 
amount of CFU/mg found internalized in or attached to the bladder tissue. Interestingly, 
the left-sided bladder tissue samples did not show a significant difference of degree of 
mucinous metaplasia between groups. There were no other statistical differences between 
groups compared to the control group for the histopathology scores. 
None of the pigs had any fibrosis in the bladder muscle or loss of bladder muscle 
integrity. Fibrosis was equally absent from the urothelium. Virtually all bladder samples 
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showed some degree of lamina propria inflammation, mostly mild to moderate. Lamina 
propria fibrosis (mild) could only be identified in one bladder tissue sample from one pig 
from the UnS group. A mild degree of sub-urothelial hemorrhage was present in 
approximately 1/5 of the bladder samples without any significant differences between 
groups. The bulk of the bladder samples showed no squamous metaplasia. Approximately 
15% of pigs had a mild degree and only 4% demonstrated a moderate degree of 
squamous metaplasia. About a third of pigs showed mild to severe ulceration of the 
bladder urothelium. A mild degree of urothelial inflammation was present in 83.3% of 
the right-sided bladder tissue samples with no significance between groups. The left-
sided samples on the other hand appeared to be significantly different with Fisher’s Exact 
test for all groups with a P-value of 0.023. Pairwise analysis however could not indicate 
any group to be significantly different from the control group. Figure 24 shows a typical 
example of bladder tissue with mucinous metaplasia and some inflammatory cells close 
to the bladder epithelium. 
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Figure 24: Pathology slide of bladder tissue with mild mucinous metaplasia and presence of some 
inflammatory cells in the lamina propria and urothelium. 
 
When comparing the total scores for the bladder tissue, the scores for the right-sided 
samples are close to being significantly different between groups with a P-value of 0.077. 
Post-hoc Dunnett’s T-Test indicates that the total bladder score for the right-sided 
samples is significantly higher in the UnS group compared to the UnEC group (Means 
+/- SD: 5.5 +/- 1.87 vs 3.17 +/- 0.75 respectively, P-value of 0.038). 
For the kidney tissue, we could not identify urothelial fibrosis in any of the pigs. Sub-
urothelial and urothelial inflammation was present in virtually all the pigs, ranging from 
mild to severe (most of the pigs had mild degree) without any statistical differences 
between groups. Squamous metaplasia was mostly absent in the kidney tissue. 
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Approximately 38% of the pigs had a mild to moderate degree of sub-urothelial 
hemorrhage. We found mucinous metaplasia in about 75% of the kidney tissue samples, 
ranging mainly from mild to moderate with only 2 samples showing severe mucinous 
metaplasia. Half of the kidney tissue samples of the pigs demonstrated a mild to moderate 
degree of urothelial ulceration with only severe ulceration in 1 pig. Once again, no 
statistical differences could be identified with Fisher’s Exact test for any of the findings. 
The total scores for the kidney tissues were comparable. 
 
3.3 Post-experimental In Vitro Evaluation of Coating 
Efficiency 
Analysis with ANOVA of in vitro planktonic bacteria demonstrated that there were no 
statistical differences between groups although there is a trend towards significance for 
Klebsiella pneumonia, Pseudomonas aeruginosa, Staphylococcus saprophyticus and 
Staphylococcus epidermidis. Post-hoc analysis with Dunnett’s T-test shows that there are 
indeed significant differences among groups. Stents coated with coating B significantly 
reduced the CFU/ml of planktonic S. saprophyticus and S. epidermidis. They showed a 
trend towards significant influence for K. pneumonia and P. aeruginosa. The stents 
coated with coating A demonstrated a significant decrease in CFU for P. aeruginosa and 
a trend towards a significant difference for K. pneumonia (Figure 25). Interestingly, the 
catheter coatings don’t seem to significantly influence the planktonic E. coli infection. 
All the data on the in vitro planktonic infection experiment with means and standard 
deviations of CFU/ml is available in Table 8. 
The same analysis was performed for bacterial attachment on the stent segments tested in 
vitro. Significant P-values were calculated for E. coli, P. aeruginosa and S. epidermidis. 
Post-hoc analysis with Dunnett’s t-test identified coating B to induce a significant 
decrease in bacterial attachment for all of the mentioned species (Figure 26). Coating A 
didn’t have a significant influence on bacterial attachment. Data is demonstrated in Table 
9. 
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 Uncoated Coating A Coating B P-value 
A vs  
Control 
B vs.  
Control 
E. coli 
1.16E9  
(1.07E8) 
1.24E8  
(1.08E8) 
7.11E7  
(8.99E7) 
0.312 0.519 0.240 
E. faecalis 
2.56E8  
(3.10E7) 
3.18E8  
(1.23E8) 
1.41E8  
(1.27E8) 
0.214 0.953 0.264 
K. 
pneumoniae 
1.82E9  
(3.70E8) 
9.96E7  
(8.61E7) 
7.93E7  
(1.35E8) 
0.092 0.216 0.065 
P. aeruginosa 
3.48E9  
(2.22E9) 
2.14E7  
(3.70E7) 
4.74E6  
(7.45E6) 
0.055 0.049 0.079 
S. 
saprophyticus 
2.29E8  
(6.63E7) 
5.50E7  
(6.79E7) 
3.62E6  
(6.25E6) 
0.064 0.402 0.043 
S. epidermidis 
3.63E8  
(2.40E8) 
8.73E7  
(1.39E8) 
3.62E6  
(6.25E6) 
0.061 0.281 0.040 
Proteus 
mirabilis 
4.62E9  
(1.25E9) 
4.28E9  
(2.93E9) 
3.23E9  
(2.35E9) 
0.714 0.831 0.635 
Table 9: Means and standard deviations of CFU/ml of planktonic bacteria from in vitro experiment. 
 
Figure 25: Means and standard deviations of CFU/ml of planktonic bacteria. *= P < 0.05. 
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 Uncoated Coating A Coating B 
P-
value 
A vs 
Control 
B vs. 
Control 
E. coli 
4.61E5 
(3.46E5) 
8.38E3 
(7.99E3) 
8.49E1 
(1.47E2) 
0.028 0.118 0.018 
E. faecalis 
2.58E5 
(1.68E5) 
8.10E5 
(6.86E5) 
4.06E5 
(5.15E5) 
0.375 0.370 1 
K. pneumoniae 
4.58E5 
(3.27E5) 
6.91E4 
(1.07E5) 
6.37E4 
(1.10E5) 
0.221 0.409 0.165 
P. auruginosa 
1.38E7 
(6.69E6) 
1.03E6 
(1.78E6) 
5.30E1 
(9.18E1) 
0.023 0.080 0.016 
S. 
saprophyticus 
1.12E5 
(1.08E5) 
1.67E4 
(2.04E4) 
1.94E3 
(3.36E3) 
0.161 0.419 0.113 
S. epidermidis 
1.01E5 
(7.78E4) 
5.92E3 
(9.23E3) 
1.94E3 
(3.36E3) 
0.019 0.221 0.012 
P. mirabilis 
5.34E6 
(1.91E6) 
7.66E6 
(3.83E6) 
8.46E6 
(5.83E6) 
0.848 0.812 0.872 
Table 10: Means and standard deviations of CFU/cm² of bacterial attachment on stents.  
 
Figure 26: Means of CFU/cm² of bacterial attachment on stents. *= P < 0.05 
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Chapter 4 
4 Discussion and Conclusions 
The projects presented in this thesis have been preceded by years of research and 
experimenting. Jeff Dalsin and co-workers started off with the notion that DOPA could 
be of use for coating PEG, a known potent antifouling molecule, onto surfaces in a robust 
way and in a high density, which had been somewhat of a challenge before (Lee et al., 
2002). 
Next came the novel idea of applying this coating onto surfaces that reside in a very harsh 
milieu such as urine (Ko et al., 2008). Ko et al had performed in vitro experiments with 
Titanium coated silicone disks on which they had applied an mPEG-DOPA3 coating. 
After submersion in pooled human urine with several uropathogens, the coated disks 
seemed to strongly resist bacterial attachment (Ko et al., 2008). Once Ko et al had 
established that the coating was functioning as expected in a urinary environment, the 
time had come to apply the coating on a urinary device that could be used in vivo. Pechey 
et al applied different formulations of the mPEG-DOPA3 coating on stent curls and 
implanted those in rabbit bladders, together with an inoculum of E. coli (Pechey et al., 
2009). Following their experiments, they identified a cross-linked polymer (Surphys-009) 
to be clearly more efficient and durable than a linear copolymer in reducing an induced 
urinary tract infection. Based on this cross-linked structure of mPEG-DOPA3, further 
research and development has led to a new DOPA-anchored copolymer formulation used 
in this project: Surphys-095. Quaternary amines and silver nitrate were added to the 
coating to theoretically increase the bactericidal effect of the coating. 
After proving the coating’s efficiency in vitro, we performed in vivo experiments with 
rabbits and pigs. 
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4.1 Rabbit Study 
4.1.1 Urine Sample Analysis 
The rabbit experiment demonstrated the devices coated with coating A to efficiently 
reduce the chance of getting an infection after E. coli inoculation by day 7 (endpoint) of 
the experiment. Contrary to what we expected, the devices coated with coating B did not 
have a significant effect on reducing infection. Whereas 83% of the rabbits implanted 
with uncoated devices had a positive urine sample at endpoint, only 36% of the rabbits in 
the coating A group and 50% of the rabbits in coating B group had a positive urine 
sample at endpoint. We assume that a larger sample size might shift the results in favor of 
the coatings. 
The degree of infection was similar between groups at endpoint indicating that if an 
infection does occur despite the antibacterial effect of the coated device, it is no different 
than in a rabbit catheterized with an uncoated catheter. This too is somewhat contrary to 
the expectations. We had expected that the animals getting an infection in the coated 
catheter groups, would have a lower degree of infection than the rabbits in the uncoated 
catheter group. 
The presence of other bacteria in the urine sample is most probably due to our bladder 
catheter model in the rabbit. To allow the rabbits a free range of mobility, we did not fit a 
urine collection bag on the catheter which resulted in an open catheter tip that potentially 
allows external bacteria to migrate to the inside of the bladder through the catheter. We 
often noticed rabbit’s excretions present on the distal part of the catheter and as such it is 
very likely that this was the source of the other bacteria in the urine samples. To prevent 
accumulation of excretions in and on the tip of the catheter as an inducing factor for 
further infection, about 0.5 to 1 cm was cut off of the external (distal) part of the catheter 
each time samples were collected. The fact that the number of rabbits with other bacterial 
species present in the urine sample increased over time (2 on day 1 and 22 on day 7) 
reflects this problem. The initial rabbit model for catheter associated urinary tract 
infection as reported by Morck and Olson (Morck et al., 1993; Olson et al., 1989) 
describes the rabbits residing in a Plexiglas cage and fed mainly with intravenous liquids. 
On occasion, they would eat. This kind of setup is not possible in our facility due to 
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general ethical rules in place requiring the animals to have free range of motion and 
environmental enrichment. The adjusted model, placing stent curls in the bladder, as 
described by Fung et al (Fung et al., 2003) is a very interesting model that has been used 
by our research group on several occasions (Cadieux et al., 2006; Pechey et al., 2009). 
However, as in that model, there is no external portion to the urinary device, it is not fully 
representative of urethral catheterization, but more of a distal stent curl in the bladder. 
 
4.1.2 Device Bacterial Attachment 
Although the bacterial attachment numbers of CFU were not statistically different 
between coatings, we did demonstrate that the rabbits that did not have an E. coli positive 
urine sample at endpoint had fewer E. coli CFU attached to the catheter segments. 
Similar results were obtained when repeating the analysis for the other bacterial species 
identified in the urine cultures, with P-values <0.05 indicating fewer CFU on the 
proximal catheter segments in the uninfected rabbits compared to the infected rabbits. We 
did indeed expect that if a rabbit does not have certain bacteria in the urine, it would not 
have that bacteria attached on the catheter surface. However, some rabbits that didn’t 
have E. coli in the day 7 urine culture did have some E. coli attached on the catheter 
surface. The most probable explanation for the E. coli attachment in uninfected rabbits is 
that the inoculated bacteria attach on the catheter surface (on conditioning film) quite 
soon after inoculation, before planktonic bacteria get eradicated by the antibacterial 
effects of the catheter coating, and that they get covered by encrustations.  
4.1.3 Tissue Bacterial Counts 
Similar to the number of infected rabbits, there were less rabbits in the coating A group 
that had bacteria attached to or invaded in the bladder tissue compared to the other 
groups. Considering that fewer rabbits had E. coli infections by day 7 in the coating A 
group, this was an expected result. However, the number of CFU of adherent or invaded 
bacteria was not different between groups. Once again we demonstrated that infected 
animals had higher CFU counts in the tissue than uninfected animals, regardless of which 
catheter had been placed. 
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4.1.4 Encrustations 
Analysis of the amount of encrustations on the devices has demonstrated that both 
coating A and B have on average more encrustations on the surface than the uncoated 
devices, however only the coating B devices had significantly more encrustations on the 
surface than the control catheters.  
Further analysis of our data confirmed the conclusion by Pechey et al that rabbits with an 
E. coli infection have less encrustations than rabbits that didn’t have an E. coli infection 
(Pechey et al., 2009). Additionally, in contrast to these findings, we demonstrated that the 
rabbits that have an infection with non-E. coli bacteria have more encrustations than the 
other rabbits. Whereas an infection with E. coli has an inverse correlation with 
encrustation, the opposite effect appears to be true for infection with non-E. coli bacterial 
species. Furthermore, the composition of the encrustations appears to be different in E. 
coli vs. non-E. coli infected rabbits. 
As mentioned in section 2.6, encrustations on the device surface are dependent of 
multiple factors, including the indwelling time, urinary pH and some predisposing and 
inhibitory protein found in the urine and in the conditioning film (Canales et al., 2009; 
Choong et al., 2001; Kawahara et al., 2012; Santin et al., 1999; Suller et al., 2005). 
Indwelling time was identical for all the rabbits and urinary pH did not seem to be 
strongly correlated to the amount of encrustations on the catheter. The high amount of 
encrustations in uninfected rabbits is due to the very nature of healthy rabbit’s urine. 
Healthy rabbit’s urine has a very cloudy and turbid appearance and is very precipitative 
in nature as a result of their herbivorous diet (Figure 27). Kiwull-Schöne and colleagues 
have demonstrated that the alkali load of the rabbit’s diet directly influences the urinary 
pH (Kiwull-Schöne et al., 2005). Whereas the urinary pH is above 8 in rabbits on a 
normal to high alkaline diet, it is strongly reduced to an average of 6.27 in rabbits on a 
low-alkaline diet (Kiwull-Schöne et al., 2005). When feeding rabbits a meat based diet, 
apparently the urine rapidly turns clear and acidic (Arunachalam and Woywodt, 2010). 
The rabbits in our facility were provided with Purina Prolab® High-Fibre Rabbit 5P25 
Lab Diet which consists mainly of soy and alfalfa sprouts that both carry a high alkali 
load. The urinary pH of the rabbits at day 0 was consistently between 8.5 and 9.0. With a 
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high baseline urinary pH, the magnesium, phosphate and calcium ions already have a 
high potential for precipitation. Despite the high-alkaline diet, we did however notice 
changes in the urinary pH during their follow-up to as low as 6.5. Although statistical 
analysis could not demonstrate a direct correlation between encrustations and urinary pH, 
interestingly we did see a significantly lower urinary pH in the rabbits that had an E. coli 
infection without any other bacterial species present in their urine culture. The fact that E. 
coli infected animals have fewer encrustations makes more sense now that we know that 
the E. coli infected rabbits have a lower urinary pH. We previously pointed out that a 
higher urinary pH will predispose the constituents in the urine to precipitate more. 
Presumably this change in pH is caused by the host’s immune response that consists of an 
influx of plasma, neutrophils, ions, cytokines and multiple other unknown factors, which 
can react with the constituents in the rabbit’s urine and thus decrease the urinary pH. 
These factors entering the bladder as part of the host’s immune response may have 
inhibitory or precipitative characteristics with regard to deposition of a conditioning film 
and encrustations onto the device surface. The results from cytokine analysis could 
potentially aid in answering the question at hand. 
Canales et al have identified several proteins influencing deposition of encrustations onto 
stent surfaces in a human urinary environment (Canales et al., 2009). The authors had 
already pointed out that injury and defense related proteins are more commonly found in 
the conditioning film of encrusted stents than in non-encrusted stents retrieved from 
humans (Canales et al., 2009). They describe immunoglobulin kappa and α1-anti-trypsin, 
proteins as important factors influencing encrustation. Santin and co-workers 
demonstrated the protective effect of Tamm-Horsfall protein and α1-microglobulin 
(Santin et al., 1999). Sadly enough, the small sample sizes of these papers (5 encrusted 
stents vs 22 non-encrusted stents in Canales et al and 2 encrusted vs 2 non-encrusted 
stents in Santin et al) reduce the power of the analysis. It would be very interesting to 
conduct this research on a vastly larger sample size and to not only analyze the proteome 
but also the microbiome of both conditioning film and patients’ urine sample.  
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Figure 27: Rabbit’s urine: A: fresh, healthy urine; B: precipitations after 1 hour; C: infected. 
 
With the aid of SEM and EDX, we were able to identify the encrustations on catheters 
from E. coli and non-E. coli infected rabbits. As can be seen on Figures 19 and 20, not 
only the amount but also the composition of the encrustations changes substantially when 
comparing devices from infected and uninfected animals. Again, we would expect the 
hydroxyapatite and struvite to deposit more frequently in non E. coli infected bladders 
with a higher pH, which was not the case here. The respective rabbits from which the 
catheters have been analyzed for SEM, had a urinary pH that never dropped below 8.5. 
Although no statistical differences were noted, we do believe that the presence of other 
bacteria and a possible change in pH is the causal factor of the difference in both 
composition and amount of encrustations on the surface of the catheters. 
 
Overall, coating A demonstrated the best performance in clearing an induced E. coli 
infection and in reducing the infection rate into the bladder tissue. The fact that Coating B 
has a higher density of both S-095 and silver, built up the expectation that the rabbits in 
the coating B group would have had even better results than the rabbits in the coating A 
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group. We did see a trend towards fewer rabbits infected in the coating B group but no 
statistical analysis could demonstrate a significant difference between the control group 
and the coating B group. This is quite contrasting with the preliminary in vitro results that 
showed eradication of not only E. coli but also other uropathogens by both coatings. It is 
possible that the rabbit urinary environment is too harsh for the coatings and that the 
coatings can’t cope with the alkaline urine and the quick deposition of crystals onto the 
catheter surface. Once the coating is covered with encrustations, the kill-by-contact effect 
of the quaternary amines seems to be nullified  
The current literature on stent or catheter related research in a rabbit model uses mainly 
one of two models: the closed drainage urinary catheter model as described by Morck and 
Olson (Morck et al., 1994, 1993; Olson et al., 1989) or the transurethral insertion of stent 
curls into the bladder which are later retrieved at necropsy (Fung et al., 2003). Our own 
model deviates somewhat from both which makes comparison to the literature somewhat 
more difficult. The most recent research on catheter and stent coatings in a rabbit model 
have evaluated Gendine, Triclosan and mPEG-DOPA3 as potential coatings preventing 
CAUTI (Cadieux et al., 2006; Hachem et al., 2009; Pechey et al., 2009). Hachem and 
colleagues adopted the rabbit model from Morck and inoculated the rabbits with E. coli 
by applying 10E9 CFU at the urethral meatus for 4 consecutive days (Hachem et al., 
2009). They compared the new coating (8 rabbits) to an uncoated silicone catheter (9 
rabbits), a hydrogel (7 rabbits) and a silver-coated catheter (7 rabbits). After 3-5 days, 
none of the rabbits with a gendine-coated catheter had a positive urine culture, whereas 
more than half of the rabbits of the other groups did. Despite the promising results, no 
publications on further research with gendine-coated catheters has emerged. Cadieux and 
his colleagues have evaluated the efficacy of Triclosan coated stent curls against P. 
mirabilis, using the Fung model (Cadieux et al., 2006). The stent curls showed significant 
reduction in P. mirabilis and were further investigated in human trials. Although they 
seem to reduce urinary tract symptoms and the incidence of symptomatic CAUTI, 
reducing the use of antibiotics, they do not significantly reduce the incidence of 
bacteriuria and stent bacterial attachment (Cadieux et al., 2009; Mendez-Probst et al., 
2012). Our own group had previously used the Fung model to investigate mPEG-DOPA3 
copolymer coatings, demonstrating significant efficiency of the cross-linked polymer S-
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009. The main issue with our model was the open catheter tip, allowing for external 
bacteria to migrate into the bladder. Regardless, we did see a beneficial effect in the 
coating A group, demonstrating efficiency in the face of bacteria flowing in. 
 
4.2 Porcine Study 
4.2.1 Urine Culture, Device and Tissue Bacterial Attachment 
Unlike the rabbit project, we included an extra control group to the pig study. 12 pigs had 
stents inserted but did not get an E. coli challenge. This group was added to allow us to 
identify the effect of the procedure and the presence of the stent on the animal’s immune 
response. In contrast to our expectations, a large amount of pigs developed a urinary tract 
infection with E. coli or any of the other bacterial species. We had expected to see that 
the saline challenge would be a good control for the E. coli challenge.  
Urinary tract infections in sows in commercial pig breeding farms are quite common to 
the extent that they are an important cause of mortality and are thought to result from the 
housing conditions of these pigs (Bellino et al., 2013; Glock and Bilkei, 2005; Karg and 
Bilkei, n.d.; Mauch and Bilkei, 2004). The prevalence of urinary tract infections in pigs 
bred for and housed in research facilities is unknown. 3 out of 48 pigs appeared to have a 
positive urine sample at day 0, before the intervention. The main reason as to why all the 
pigs eventually did get a urinary tract infection is most probably due to the procedure. 
Despite the three day acclimatization period that all the pigs had before proceeding with 
the procedure, most of the pigs were still dealing with the stress of moving from the farm 
where they were bred to the University animal facility. Pigs are very prone to stress and 
then usually get diarrhea. Despite our best efforts to perform a sterile procedure for stent 
placement, it was almost inevitable to have some fecal soiling of the operation field. This 
means that by placing the stent in the pig, we probably inoculated the pigs urinary tract 
with fecal flora and probably in a higher concentration than the 10E7 of E. coli that we 
inoculated the pigs with at the end of the procedure. 
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The fact that we didn’t see any statistical differences for any of the groups regarding 
urinary tract infections, bacterial attachment and tissue attachment and internalization is 
to be explained by multiple factors. First of all and probably very important in this model, 
is that the inoculum of fecal bacteria that was inserted with the procedure was probably 
that concentrated with such a high amount of bacteria that the stent coating was 
overwhelmed with the plethora of bacteria and the degree of infection and could not deal 
with the infection because of the sheer abundance of bacteria. Additionally, the post-
animal study in vitro experiments should be taken into account. All the devices used for 
every part of this study were produced at the same time, before the study started. As the 
rabbit experiment was conducted first, the coated stents had not been stored as long as for 
the pig study. In contrast to the pre-study in vitro experiments, we could only 
demonstrate significant in vitro activity of the stents coated with Coating B for S. 
saprophyticus and S. epidermidis. Coating A had significant activity against P. 
aeruginosa. Neither of the stents was efficient in clearing the planktonic E. coli, which 
was the core goal of our study. It’s safe to say that the coating may have lost some of its 
activity from the time of production to the time of insertion in the pigs and of in vitro re-
assessment. We can only hypothesize why this would have happened. The SEM pictures 
of the coated stents showed the coating to be homogeneously distributed on the stent 
surface. They also quite nicely showed the difference in S-095 density and the presence 
of the silver particles. The DOPA molecule of S-095 was covalently bonded with the 
amine (NH2) groups on the stent surface. We know that the coating is very hydrophilic 
and ‘wants’ to interact with water. It is possible that water got through the packaging and 
that the coating started interacting with it. On the other hand, the coating may have 
become somewhat brittle and more fragile at the surface. The shear stress of placing the 
stent into the pigs urinary tract may have been that high that the coating sloughed off 
during the process. 
4.2.2 Encrustations 
Although all the pigs had a positive urine sample at endpoint, none of the stents retrieved 
from the pigs had any encrustations on the surface. This is in stark contrast to our 
findings in the rabbits, where we found a high amount of encrustations on all of the 
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devices. In rabbits, an inverse correlation was demonstrated between infection and 
encrustation. It would however not be correct to extrapolate this statement to the pig 
model. As mentioned in the background chapter of this manuscript, the presence of 
encrustations is influenced by multiple factors. It’s possible that the lack of encrustations 
is due to a more acidic urine (at which phosphate and magnesium would not precipitate 
as easily as at an alkaline pH). 
4.2.3 Histopathology 
Histopathology analysis demonstrated that the right-sided bladder tissue from pigs in the 
uncoated stent saline group showed a higher degree of mucinous metaplasia than the 
other animals. We controlled for all the possible other confounders (that we have data 
for) such as degree of infection of any of the bacterial species cultured, amount of CFU in 
the bladder tissue, amount of CFU on the stent surface, OR-time and urinary pH. None of 
these factors had any influence on the mucinous metaplasia. Similarly, the total scores for 
the right-sided bladder tissue samples was significantly higher for the UnS pigs compared 
to the UnEC pigs. The strange fact that the uncoated saline challenge pigs had more 
histopathology changes (they were supposed to be negative controls for the uncoated 
stent E. coli challenge pigs) is probably due to the small sample size of data that we have 
for the histopathology. For each of the groups, we only have histopathology data for 6 
animals in each arm. We assume that the significant differences noted in the statistical 
analysis are by pure chance alone rather than due to an actual detrimental effect of the 
polyurethane stent on the bladder tissue. Additionally, we would have expected the 
results in the left-sided tissue samples to be somewhat similar to the right-sided if the 
polyurethane catheter would actually have had a negative effect on the tissue. The 
absence of any significant differences for any of the other histopathology changes 
measured between the groups strengthens this hypothesis. 
The porcine model has been extensively used for stent related research, as mentioned in 
section 3.2. The bulk of these experiments however deal with biodegradable and 
symptom-reducing stent designs and biomaterials which is in contrast to our own current 
study on anti-fouling and anti-bacterial coatings on stents. The theory of biodegradable 
stents on the other hand is increased biocompatibility, which in turn should translate into 
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a lower device associate urinary tract infection rate. The Uriprene™ stent has been 
reported to induce fewer urinary tract infections than a control stent (Hadaschik et al., 
2008). All animals in this study were given antibiotic prophylaxis. A newer formulation 
of the Uriprene™ stent that dissolves in 4 weeks instead of 10 weeks (as the previous 
formulation did) on the other hand had a higher infection rate than the control stents 
(Chew et al., 2013). Pigs did not get prophylaxis in this study. In the study by Lumiaho 
and colleagues on a short helical biodegradable stent, no infections were reported in the 
pigs (Lumiaho et al., 2011). The short segmental biodegradable stent has the advantage of 
not having a portion of the stent in the bladder which conceptually could have a lower 
risk of getting infected. They bypassed the potentially soiled urethra by placing the stents 
through a small cystotomy. Kallidonis and Liatsikos compared cytostatic-drug-coated 
metal stents to bare metal stents for long term stenting of malignant ureteral obstruction 
in a porcine model (Kallidonis et al., 2011; Liatsikos et al., 2007). Infection rates were 
not mentioned in these studies. 
In conclusion, it is currently impossible to adequately compare our results to the literature 
as our research is currently the only porcine study performed with the goal of testing a 
ureteral stent coating preventing encrustations and urinary tract infections. 
 
4.3 Future Directions 
The discrepancy between the rabbit data and the pig data, together with the results of the 
post-animal study in vitro experiments has indicated that the coating is subject to a 
certain shelf-life. This shelf-life of the device coatings will need to undergo some further 
evaluation and testing. Durability testing to ensure the coatings are not displaced at the 
time of insertion as well as testing of the packaging will require further study. 
The rabbit model has some limitations due to ethical rules in place. The rabbit model for 
catheter associated urinary tract infection that was proposed by Morck and others (Morck 
et al., 1994, 1993; Olson et al., 1989) had the rabbits sitting in a glass or Plexiglas cage 
without any range of motion and with an intravenous catheter as their main source of 
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fluid intake and nutrition. This of course allowed the researchers to have a collection bag 
fitted on the catheter, which prevents the influx of any bacteria from outside to inside. As 
the animal ethics require the animals to have free range of motion, we could not fit a 
collection bag on the catheter and thus could not prevent bacteria to migrate into the 
bladder via the catheter. 
The pig model was chosen for our model of stent related infection because the 
availability of the model and anatomical resemblance to the human urinary tract. Current 
project shows that although the theory of this model was quite logical and very feasible, 
the results have raised methodological issues. Alternate models or a different approach of 
placing the stents (via cystotomy in lieu of transurethrally) need to be considered for 
future in vivo work. 
Taking the theoretical background, preceding and current research into account, 
especially considering the pitfalls of the current model, we do believe that the currently 
developed coatings deserve further research and may in the future be applied on stents 
and catheters for human use. 
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